Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and Acute Relapsing Multiple Sclerosis

fingolimod hydrochloride has been researched along with Acute Relapsing Multiple Sclerosis in 605 studies

Research

Studies (605)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (0.83)29.6817
2010's381 (62.98)24.3611
2020's219 (36.20)2.80

Authors

AuthorsStudies
Bianco, A; Centonze, D; De Arcangelis, V; De Fino, C; De Luca, G; Di Lemme, S; Di Tommaso, V; Evangelista, L; Fantozzi, R; Lucchini, M; Mirabella, M; Pastorino, R; Presicce, G; Totaro, R1
Gaughan, M; Lally, A; McGuigan, C; O'Higgins, L1
Abouelfath, A; Blin, P; Bosco-Lévy, P; Brochet, B; Debouverie, M; Diez, P; Droz-Perroteau, C; Guillemin, F; Heinzlef, O; Lassalle, R; Lignot, S; Louapre, C; Maillart, E1
Al-Khedr, A; Alroughani, R; Andersen, JB; Berger, E; Bourre, B; Boz, C; Bramow, S; Butzkueven, H; Buzzard, K; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Ciron, J; Clavelou, P; Csepany, T; De Sèze, J; Debouverie, M; Defer, G; Duquette, P; Edan, G; Ferraro, D; Frederiksen, JL; Girard, M; Gout, O; Grammond, P; Grand'Maison, F; Granella, F; Hankiewicz, K; Havrdova, EK; Heinzlef, O; Horakova, D; Izquierdo, G; Jensen, MB; Kalincik, T; Koch-Henriksen, N; Labauge, P; Labeyrie, C; Laplaud, D; Lebrun-Frénay, C; Lechner-Scott, J; Lefort, M; Leray, E; Lugaresi, A; Magyari, M; Maillart, E; Maimone, D; Mathiesen, HK; Maubeuge, N; Maurousset, A; McCombe, P; Montcuquet, A; Moreau, T; Nifle, C; Onofrj, M; Ozakbas, S; Patry, I; Patti, F; Pelletier, J; Pfleger, CC; Pottier, C; Prat, A; Prevost, J; Rasmussen, PV; Ruet, A; Schreiber, KI; Sellebjerg, FT; Sharmin, S; Skibina, O; Slee, M; Soerensen, PS; Sola, P; Spitaleri, D; Stankoff, B; Terzi, M; Thouvenot, E; Trojano, M; Turkoglu, R; Van der Walt, A; Van Wijmeersch, B; Vucic, S; Vukusic, S; Wahab, A; Yamout, B; Zephir, H1
Annovazzi, P; Baroncini, D; Bonavita, S; Brambilla, L; Caleri, F; Capobianco, M; Carotenuto, A; Cavalla, P; Clerico, M; Cocco, E; Cordioli, C; De Mercanti, SF; Di Francescantonio, V; Fenu, G; Frau, J; Gallo, A; Giugno, A; Grasso, R; Iodice, R; La Gioia, S; Lapucci, C; Laroni, A; Lus, G; Maniscalco, GT; Russo, CV; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Torri Clerici, V; Zaffaroni, M1
Berthele, A; Bussas, M; Eichinger, P; Gaser, C; Grahl, S; Hemmer, B; Kirschke, J; Mühlau, M; Wiestler, B; Zimmer, C1
Anagnostouli, M; Chrousos, GP; Dalakas, M; Evangelopoulos, ME; Gontika, M; Markoglou, N; Skarlis, C; Stefanis, L; Velonakis, G1
Alroughani, R; Barnett, M; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Duquette, P; Eichau, S; Girard, M; Grammond, P; Gresle, M; Hodgkinson, S; Jokubaitis, VG; Kalincik, T; Karabudak, R; Kermode, AG; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; McCombe, P; Monif, M; Prevost, J; Skibina, O; Slee, M; Stankovich, J; Taylor, B; van der Walt, A; Van Hijfte, L; van Pesch, V; Yeh, W; Zhong, M1
Haapasalo, A; Hartikainen, P; Herukka, SK; Huber, N; Jääskeläinen, O; Kokkola, T; Kontkanen, A; Lohioja, T; Niiranen, M; Remes, AM; Selander, T; Simula, S; Solje, E; Tertsunen, HM1
Acar-Ozen, P; Ayvacioglu Cagan, C; Bayraktar-Ekincioglu, A; Cakan, M; Goncuoglu, C; Karabudak, R; Karabulut, E; Tuncer, A1
Cai, T; Chitnis, T; Dahal, K; Hou, J; Kim, N; Weiner, H; Xia, Z1
Acosta, C; Alroughani, R; Boz, C; Butzkueven, H; De Luca, G; Dort, T; Duquette, P; Ferraro, D; Freudensprung, U; Grammond, P; Grand'Maison, F; Granella, F; Havrdova, E; Herring, WL; Horakova, D; Hupperts, R; Hyde, R; Izquierdo, G; Jokubaitis, VG; Kalincik, T; Lechner-Scott, J; Lugaresi, A; Oreja-Guevara, C; Pearson, I; Pucci, E; Rozsa, C; Sola, P; Spelman, T; Tempest, M; Terzi, M; Trojano, M; van der Walt, A; Van Pesch, V; Zhang, Y1
Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Fabacher, T; Fleury, M; Gaultier, C; Goudot, M; Kremer, L1
Albrecht, H; Ettle, B; Haas, J; Klotz, L; Lang, M; Lang, S; Lassek, C; Schmidt, S; Schulze-Topphoff, U; Winkelmann, VE; Ziemssen, T1
Hartung, HP; Korsen, M; Meuth, SG; Pfeuffer, S; Rolfes, L1
Dimitri, D; Pourcher, V1
Amato, MP; Battaglia, MA; Brambilla, L; Brescia Morra, V; Capobianco, M; Cavalla, P; Comi, G; De Luca, G; Ferraro, D; Filippi, M; Granella, F; Iaffaldano, P; Lepore, V; Lucisano, G; Lugaresi, A; Lus, G; Malucchi, S; Maniscalco, GT; Manni, A; Moiola, L; Montepietra, S; Mosconi, P; Paolicelli, D; Patti, F; Pesci, I; Petracca, M; Ponzio, M; Ragonese, P; Sola, P; Tedeschi, G; Toscano, S; Totaro, R; Trojano, M; Vianello, M1
Clarelli, F; Esposito, F; Ferrè, L; Filippi, M; Mascia, E; Ottoboni, L; Provero, P; Santoro, S; Sferruzza, G; Sorosina, M1
Bielen, I; Draganić, P; Klepac, N; Košćak Lukač, J; Sremec, J; Tomasović, S1
Alonso, R; Barboza, A; Burgos, M; Carra, A; Chertcoff, A; Fernandez Liguori, N; Gaitán, MI; Halfon, MJ; Lazaro, L; Liwacki, S; Luetic, G; Mainella, C; Menichini, ML; Miguez, J; Orzuza, G; Palavecino, A; Pappolla, A; Patrucco, L; Pierdabuena, R; Pigretti, S; Pita, C; Recchia, L; Ruiz, E; Silva, B; Steinberg, J; Tkachuk, VA; Ysrraelit, MC; Zanga, G; Zentil, G1
Askari, M; Ghaffary, EM; Ghajarzadeh, M; Ghoshouni, H; Mirmosayyeb, O; Shaygannejad, V1
Andrade, M; Boldrini, VO; Brandão, CO; Carneiro, RPD; Damasceno, A; Farias, AS; Ferrari, B; Longhini, ALF; Marques, AM; Moraes, AS; Quintiliano, RPS; Santos, I; Santos, LMB; Stella, CRAV1
Berger, E; Bourre, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Ciron, J; Clavelou, P; Couturier, J; De Sèze, J; Debouverie, M; Defer, G; Edan, G; Gout, O; Hankiewicz, K; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Maillart, E; Maurousset, A; Montcuquet, A; Moreau, T; Nasr, HB; Neau, JP; Pelletier, J; Pottier, C; Rollot, F; Ruet, A; Stankoff, B; Thouvenot, E; Vukusic, S; Wiertlewski, S; Zephir, H1
Alroughani, R; Butzkueven, H; Buzzard, K; Eichau, S; Grammond, P; Havrdova, EK; Hodgkinson, S; Horakova, D; Izquierdo, G; Kalincik, T; Kappos, L; Lechner-Scott, J; Malpas, CB; Patti, F; Roos, I; Sharmin, S; Skibina, O1
Aydemir, A; Bezemer, I; Butzkueven, H; Korhonen, P; Moore, N; Sabidó, M; Sõnajalg, J1
Počíková, Z; Štěpánová, R; Tichá, V; Vytlačil, J1
Ács, P; Bencsik, K; Biernacki, T; Csányi, A; Cseh, B; Csépány, T; Dobos, E; Fricska-Nagy, Z; Füvesi, J; Horváth, L; Kincses, TZ; Kovács, K; Nagy, Z; Rózsa, C; Sandi, D; Vécsei, L1
Celius, EG; Høgestøl, EA; Myhr, KM; Nygaard, GO; Skattebøl, L; Sowa, P; Torgauten, H; Torkildsen, Ø1
Atula, S; Järvinen, E; Kuusisto, H; Rauma, I; Ryytty, M; Sipilä, JOT; Soilu-Hänninen, M; Viitala, M1
Gębka-Kępińska, B; Sowa, P; Zięba, N1
Chandran, S; Connick, P; Foley, P; Glasmacher, SA; Hassan, Z; Kearns, PK; Reetz, K; Tauber, S1
Bove, RM; Gelfand, JM; Green, AJ; Guo, CY; Hsu, WY; Li, A; McPolin, K; Merrill, S; Rowles, WM1
Bawand, R; Fathoallahi, N; Ghiasian, M; Moradi, A1
Al-Khedr, A; Alroughani, R; Andersen, JB; Ben Nasr, H; Berger, E; Bourre, B; Boz, C; Bramow, S; Butzkueven, H; Buzzard, K; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Ciron, J; Clavelou, P; Csepany, T; De Sèze, J; Debouverie, M; Defer, G; Dimitri-Boulos, D; Duquette, P; Edan, G; Eichau, S; Ferraro, D; Frederiksen, JL; Girard, M; Gout, O; Grammond, P; Grand'Maison, F; Granella, F; Hankiewicz, K; Havrdova, EK; Heinzlef, O; Hilt Christensen, CC; Horakova, D; Izquierdo, G; Jensen, MB; Kalincik, T; Karabudak, R; Koch-Henriksen, N; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Lechner-Scott, J; Lefort, M; Leray, E; Lugaresi, A; Magyari, M; Maillart, E; Maimone, D; Mathiesen, HK; Maubeuge, N; Maurousset, A; McCombe, P; Montcuquet, A; Moreau, T; Nifle, C; Onofrj, M; Ozakbas, S; Patti, F; Pelletier, J; Pottier, C; Prat, A; Prevost, J; Rasmussen, PV; Ruet, A; Schreiber, KI; Sellebjerg, F; Sharmin, S; Shaygannejad, V; Skibina, O; Slee, M; Soerensen, PS; Sola, P; Spitaleri, D; Stankoff, B; Terzi, M; Thouvenot, E; Trojano, M; Turkoglu, R; Van der Walt, A; Van Wijmeersch, B; Vucic, S; Vukusic, S; Wahab, A; Yamout, B; Zephir, H1
Holko, P; Kawalec, P; Osiecka, O; Śladowska, K1
Cannizzaro, M; Clarelli, F; Colombo, B; Comi, G; Esposito, F; Ferré, L; Filippi, M; Giordano, A; Martinelli, V; Moiola, L; Sangalli, F1
Acar Ozen, P; Anlar, B; Parlak, S; Solmaz, I; Tuncer, A1
Holman, SP; Kasheke, GDS; Robertson, GS1
Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M1
Callens, A; Coustans, M; Edan, G; Jourdain, A; Lallement, F; Laplaud, D; Le Page, E; Leblanc, S; Leray, E; Michel, L; Videt, D; Wiertlewski, S1
Boyko, AN1
Al-Iedani, O; Lea, R; Lechner-Scott, J; Ramadan, S; Ribbons, K1
Apóstolos, SLP; Boaventura, M; Campana, IG; Mendes, NT; Teixeira, LS1
Aguera-Morales, E; Al-Asmi, A; Alroughani, R; Amato, MP; Ampapa, R; Bakchine, S; Barnett, MH; Ben, NH; Berger, E; Bourre, B; Boz, C; Butler, EG; Butzkueven, H; Buzzard, K; Cabre, P; Cartechini, E; Casey, R; Castillo-Trivino, T; Ciron, J; Clavelou, P; Csepany, T; de Gans, K; De Seze, J; Debouverie, M; Edan, G; Eichau, S; Fragoso, YD; Gerlach, O; Girard, M; Gouider, R; Gout, O; Grammond, P; Grand'Maison, F; Havrdova, EK; Heinzlef, O; Hodgkinson, S; Horakova, D; Izquierdo, G; Kalincik, T; Kappos, L; Khoury, SJ; Labauge, P; Labeyrie, C; Laplaud, DA; Laureys, G; Lebrun-Frenay, C; Lechner-Scott, J; Leray, E; Macdonell, RA; Maillart, E; Malpas, C; Maubeuge, N; McCombe, PA; Moreau, T; Ozakbas, S; Patti, F; Pelletier, J; Prat, A; Prevost, J; Ramo-Tello, CM; Roos, I; Sánchez-Menoyo, JL; Shaygannejad, V; Sidhom, Y; Skibina, O; Slee, M; Sotoca, J; Soysal, A; Spitaleri, DLA; Stankoff, B; Terzi, M; Thouvenot, E; Turkoglu, R; Van der Walt, A; Van Hijfte, L; Van Pesch, V; Vucic, S; Vukusic, S; Wahab, A; Yamout, BI; Zephir, H1
Al-Araji, SA; Chard, DT; Ciccarelli, O; Sahi, N; Trip, SA1
De Sèze, J; Edan, G; Kerbrat, A; Laplaud, DA; Le Page, E; Lebrun-Frenay, C; Lefort, M; Leguy, S; Leray, E; Lescot, L; Michel, L; Vukusic, S; Wiertlewski, S1
Apóstolos-Pereira, SL; Callegaro, D; Castrillo, BB; Silva, GD1
Cano, S; Elliott, E; Jivraj, F; Kang, S; Kapadia, S; Reedie, S; Rock, M; Strzok, S1
Bajeux, E; Chappuis, M; Edan, G; Kerbrat, A; Laplaud, D; Le Page, E; Michel, L; Rousseau, C; Wiertlewski, S1
Ataei, S; Esfahani, ME; Jenabi, E; Sahraian, MA; Salehi, AM1
Haug, U; Kollhorst, B; Platzbecker, K; Wentzell, N1
Aykaç, S; Eliaçık, S1
Davani, DN; Ghajarzadeh, M; Najdaghi, S; Shaygannejad, V1
Dababneh, D; Montalban, X; Muccilli, A; Rotstein, D; Saab, G; Shah, P; Solomon, JM; Sormani, MP; Ye, XY1
Cristiano, E; Pappolla, A; Patrucco, L; Rojas, JI; Sánchez, F1
Akgün, K; Constantinescu, V; Ziemssen, T1
Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Karabudak, R; Khoury, SJ; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Macdonell, R; Merlo, D; Monif, M; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Roos, I; Skibina, O; Slee, M; van der Walt, A; Van Pesch, V; Zhou, Z; Zhu, C1
Chang, X; Dong, Q; Huang, W; Lu, C; Lu, J; Ngew, KY; Quan, C; Tan, H; Wang, L; Wang, M; Wu, M; Wu, X; Xiao, Y; Yu, J; ZhangBao, J; Zhao, C; Zhou, L1
AlQudah, A; Ennab, W; Gammoh, O; Hmedat, A; Kifaieh, A; Qnais, E; Rob, OAA; Weshah, F1
Al-Iedani, O; Alshehri, A; Khormi, I; Koussis, N; Lea, R; Lechner-Scott, J; Ramadan, S1
Comabella, M; Fissolo, N; Gutierrez, L; Montalban, X; Pappolla, A; Perez-Hoyos, S; Rio, J; Sanchez, A; Villar, LM1
Benet, LZ; Liu, W; Wang, Z; Waubant, EL; Yu, Z; Zhai, S1
Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B1
Barritt, AW; Berger, JR; Das, E; Dizdarevic, S; Fisniku, LK; Morley, N; Nicholas, R; Saha, R; Seymour, M; Vera, J; Vundavalli, S1
Al-Mujaini, AS; Al-Rashdi, AA; Sabt, BI1
Anvari, K; Huehnchen, P; Kriedemann, H; Müller-Jensen, L; Siffrin, V1
Aguglia, U; Amato, MP; Angelucci, E; Boffa, G; Brescia Morra, V; Caniatti, LM; Cocco, E; Conte, A; Cottone, S; De Luca, G; Filippi, M; Galgani, S; Gasperini, C; Granella, F; Iaffaldano, P; Inglese, M; Lugaresi, A; Lus, G; Mancardi, GL; Mariottini, A; Massacesi, L; Meletti, S; Moiola, L; Nistri, R; Patti, F; Repice, AM; Romano, S; Saccardi, R; Salemi, G; Sbragia, E; Signori, A; Sola, P; Sormani, MP; Trojano, M; Zaffaroni, M1
Agan, K; Baba, C; Balcı, BP; Boz, C; Demirkıran, M; Efendi, H; Guler, S; Karabudak, R; Karahan, SZ; Kıylıoğlu, N; Köseoğlu, M; Ozakbas, S; Sevim, S; Soysal, A; Terzi, M; Tuncer, A; Turan, ÖF; Turkoglu, R; Yetkin, MF; Yüceyar, N1
Fukumoto, S; Isobe, N; Masaki, K; Matsushita, T; Tanaka, E; Watanabe, M; Yamasaki, R1
Alroughani, R; Boz, C; Butzkueven, H; Csepany, T; Grammond, P; Grand'Maison, F; Granella, F; Horakova, D; Kalincik, T; Lechner-Scott, J; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Spelman, T; Terzi, M; van der Walt, A; Zhu, C1
Aguera-Morales, E; Al-Asmi, A; Al-Harbi, T; Alroughani, R; Altintas, A; Ampapa, R; Barnett, M; Bergamaschi, R; Blanco, Y; Boz, C; Butzkueven, H; Buzzard, K; Cartechini, E; Castillo-Triviño, T; Csepany, T; de Gans, K; Deri, N; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Fragoso, Y; Gerlach, O; Girard, M; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Izquierdo, G; Kalincik, T; Karabudak, R; Laureys, G; Lechner-Scott, J; Lugaresi, A; Maimone, D; Malpas, C; McCombe, P; McGuigan, C; Moore, F; Onofrj, M; Ozakbas, S; Patti, F; Petersen, T; Prat, A; Prevost, J; Ramo-Tello, C; Roos, I; Sa, MJ; Sanchez-Menoyo, JL; Schepel, J; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Skibina, O; Sola, P; Solaro, C; Soysal, A; Spitaleri, D; Terzi, M; Trevino-Frenk, I; Turkoglu, R; van der Walt, A; van Pesch, V; Van Wijmeersch, B; Yamou, B1
Berger, É; Bigaut, K; de Sèze, J; Debouverie, M; Gauer, L; Moreau, T1
Berger, T; Di Pauli, F; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F1
Fakih, AU; Naser Moghadasi, A; Paybast, S; Sahraian, MA1
Dardiotis, E; Doskas, T; Fakas, N; Grigoriadis, N; Iliopoulos, I; Karageorgiou, K; Maltezou, M; Mitsikostas, DD; Orologas, A; Vikelis, M1
Cocco, E; Fenu, G; Lorefice, L; Pilotto, S; Zoledziewska, M1
Angelucci, F; Klimová, B; Krejsek, J; Novotny, M; Pavelek, Z; Peterka, M; Sejkorova, I; Sobisek, L; Soucek, O; Stourac, P; Valis, M; Vysata, O1
Alkrenawi, M; Appel, S; Gelfand, A; Hovel, N; Menendez, L; Milo, R; Nitsan, Z; Osherov, M1
Chou, CH; Lin, W; Lin, YK; Sung, YF; Tsai, CK; Yang, FC1
Canpolat, M; Kum, YE; Pamukçu, Ö1
Chitnis, T; Gonzalez-Martinez, A; Healy, BC; Lokhande, H; Patel, R; Paul, A; Polgar-Turcsanyi, M; Saxena, S; Weiner, HL1
Alroughani, R; Barnett, M; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Duquette, P; Eichau, S; Garber, J; Gerlach, O; Girard, M; Grammond, P; Grand'Maison, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kermode, AG; Khoury, SJ; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, RAL; Merlo, D; Monif, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Sa, MJ; Skibina, O; Slee, M; Terzi, M; van der Walt, A; Van Hijfte, L; Van Pesch, V; Van Wijmeersch, B; Weinstock-Guttman, B; Yamout, B; Zhou, Z; Zhu, C1
Everest, E; Gorkey, OD; Gulec, B; Koc, M; Saip, S; Siva, A; Tutuncu, M; Uygunoglu, U1
Al-Naqshbandi, M; El Ayoubi, NK; Ghanim, Z; Habahbeh, M; Hatem, A; Joudi, H; Raki, A; Sahraian, MA1
Aydinlar, A; Gullu, G; Gunay-Polatkan, S; Koc, ER; Sigirli, D; Turan, OF1
Brownlee, WJ; Duncan, J; Haghikia, A; Harty, GT; Hayward, B; Kayaniyil, S; Khan, Z; Millar, S; Waser, N1
Aguera-Morales, E; Al-Asmi, A; Al-Harbi, TM; Alroughani, R; Altintas, A; Ampapa, R; Bergamaschi, R; Boz, C; Butzkueven, H; Cartechini, E; Castillo-Trivino, T; Csepany, T; de Gans, K; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Gerlach, O; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Laureys, G; Lechner-Scott, J; Lugaresi, A; Malpas, CB; McCombe, PA; McGuigan, C; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Roos, I; Sa, MJ; Sánchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Sidhom, Y; Slee, M; Sola, P; Solaro, C; Stuart, EA; Terzi, M; Treviño Frenk, I; van der Walt, A; Vucic, S; Yamout, B1
Koca, N; Seferoğlu, M1
Aguera-Morales, E; Al-Asmi, A; Alroughani, R; Atkins, H; Blanco, Y; Bo, L; Burman, J; Butzkueven, H; Cartechini, E; Castillo-Triviño, T; Csepany, T; de Gans, K; Duquette, P; Fragoso, Y; Freedman, MS; Garber, J; Gerlach, O; Gouider, R; Grigg, A; Havrdova, EK; Hodgkinson, S; John, N; Kalincik, T; Karabudak, R; Kermode, A; Khoury, SJ; Kozak, T; Krasulova, E; Kuhle, J; Laureys, G; Lechner-Scott, J; Lehmann, AK; Lugaresi, A; Macdonell, R; Maimone, D; Massey, J; McCombe, P; Mrabet, S; Ozakbas, S; Patti, F; Roos, I; Sa, MJ; Sanchez-Menoyo, JL; Sharmin, S; Sharrack, B; Skibina, O; Slee, M; Snowden, JA; Spitaleri, D; Sutton, I; Taylor, B; Torkildsen, Ø; Trnený, M; Turkoglu, R; van der Walt, A; Van Hijfte, L; van Pesch, V; Weinstock-Guttman, B; Willekens, B; Withers, B1
Akçalı, A; Altunan, B; Altunrende, B; Balcı, FB; Bingöl, A; Boz, C; Efendi, H; Güler, S; Günal, Dİ; Köseoğlu, M; Kotan, D; Sunter, G; Tamam, Y; Terzi, M; Turan, ÖF; Turgut, N; Ünal, A; Yildirim, KA1
Engin, E; Günal, D; Sünter, G; Vural, E; Yıldırım, KA1
Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Dentel, C; Fickl, A; Fleury, M; Gaultier, C; Kolitsi, I; Kremer, L; Lanotte, L; Moreau, A; Mostoufizadeh, S; Sellal, F1
Boudot de la Motte, M; Garmendia, A; Gassama, S; Lejeune, FX; Louapre, C; Maillart, E; Papeix, C; Roux, T1
Baradaran, B; Barpour, N; Dabbaghi, R; Hosseinpourfeizi, M; Rahmani, S; Rajabi, A; Safaralizadeh, R1
Chamova, T; Chervenkov, V; Ivanova, S; Kaprelyan, A; Kipriyanovska, K; Milanov, I; Slavov, G; Tournev, I1
Adams, O; Aktas, O; Albrecht, P; Gembruch, O; Gold, R; Hadisurya, J; Hartung, HP; Hellwig, K; Kraemer, M; Pilgram-Pastor, S; Schneider-Hohendorf, T; Schwab, N; Sinnecker, T; Wrede, K1
Comi, G; Falini, A; Filippi, M; Moiola, L; Preziosa, P; Riccitelli, GC; Rocca, MA; Rodegher, M; Signori, A; Storelli, L1
Décard, BF; Derfuss, T; Diebold, M; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Tsagkas, C1
Akçalı, A; Akman, G; Altintas, A; Altunrende, B; Balcı, BP; Boz, C; Demirkıran, M; Efendi, H; Ekmekci, Ö; Kale, N; Karabudak, R; Karahan, SZ; Köseoğlu, M; Kurne, A; Ozakbas, S; Özer, B; Sevim, S; Soysal, A; Terzi, M; Turan, ÖF; Turkoglu, R; Yüceyar, N1
Badilini, F; Bartezaghi, M; Bianco, A; Bonavita, S; Chisari, C; De Angelis, G; Frigerio, F; Laroni, A; Mancardi, G; Mirabella, M; Montano, N; Patti, F; Rossi, S; Sparaco, M; Turrini, R; Vanoli, E1
Abdel-Dayem, MA; Gameil, NM; Shaker, ME1
Akçay, Hİ; Altunrende, B; Çalışkan, Z; Çınar, SA; Eraksoy, M; Gündüz, T; İçöz, S; Kasap, M; Kürtüncü, M; Ötünç, G; Türkoğlu, R; Tüzün, E; Ulusoy, C; Yılmaz, V1
Amato, MP; Avolio, C; Bonavita, S; Brescia Morra, V; Capobianco, M; Cocco, E; Comi, G; Conte, A; De Luca, G; De Robertis, F; Gasperini, C; Gatto, M; Gazzola, P; Iaffaldano, A; Iaffaldano, P; Lucisano, G; Lus, G; Maimone, D; Mallucci, G; Maniscalco, GT; Manni, A; Marfia, GA; Paolicelli, D; Patti, F; Pesci, I; Pozzilli, C; Rovaris, M; Salemi, G; Salvetti, M; Spitaleri, D; Totaro, R; Trojano, M; Zaffaroni, M1
Cohen, J; Haas, J; Hartung, HP; Jeffery, D; Meier, DP; Meinert, R; Silva, D1
Alping, P; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Luna, G; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M1
Alvarez, E; Bermel, RA; Cohen, JA; Corboy, JR; Fox, RJ; Harris, H; Hersh, CM; Nair, K; Ontaneda, D; Vollmer, B; Vollmer, T1
Adamczyk-Sowa, M; Bartosik-Psujek, H; Brola, W; Chorąży, M; Collin, F; Czarnowska, A; Kapica-Topczewska, K; Kochanowicz, J; Kułakowska, A; Kwaśniewski, M; Tarasiuk, J1
Naser Moghadasi, A; Navardi, S; Sahraian, MA1
Brown, B; Kolodny, S; Meng, X; Osborne, JA; Weiss, JL; Williams, IM1
Brück, W; Grondey, K; Häusser-Kinzel, S; Husseini, L; Pellkofer, HL; Rowold, C; Seeger, I; Traub, JW; Weber, MS1
Fan, G; Hopkins, RS; Kim, E; Okada, CY; White, KP; Wills, A1
Bø, L; Lereim, RR; Myhr, KM; Nystad, AE; Oveland, E; Torkildsen, Ø; Wergeland, S1
Feige, J; Schernthaner, C; Sellner, J; Wipfler, P1
Kimiskidis, VK; Moschou, M; Notas, K; Orologas, A; Papadaki, E1
Altobelli, C; Anastasio, P; Barbarulo, AM; Conchiglia, G; D'Amico, A; Di Pietro, A; Fratta, M; Lus, G; Rossi, F; Signoriello, E; Ugga, L1
Gross, CC; M Grauer, O; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Rolfes, L; Ruck, T; Schmidt-Chanasit, J; Schulte-Mecklenbeck, A; Thomas, C; Wiendl, H1
Akgün, K; Matko, S; Odendahl, M; Tonn, T; Ziemssen, T1
Chen, CY; Cui, YM; Li, M; Ma, LY; Tian, X; Wu, Y; Yang, T; Zhou, S; Zhou, Y1
Järvinen, E; Lundström, T; Mankinen, P; Niskala, U; Ruutiainen, J; Soini, E; Sumelahti, ML1
Emming, S; Gobbi, C; Monticelli, S; Sacco, R; Zecca, C1
Briner, M; Chan, A; Daponte, A; Diem, L; Evangelopoulos, ME; Findling, O; Gold, R; Hoepner, R; Kilidireas, C; Miclea, A; Salmen, A1
Kao, D; Mehta, R; Patterson-Lomba, O; Pelletier, C; Sheffield, JK; Signorovitch, J; Stonehouse, T; Swallow, E; Yin, L1
Costa, J; Guerreiro, R; Miguel, LS; Pinheiro, B1
Caire-Herrera, LE; Casallas-Vanegas, A; Coss-Rovirosa, F; Flores-Rivera, J; Gómez-Figueroa, E; Salado-Burbano, J1
Bonavita, S; Casertano, S; Lanzillo, R; Lus, G; Maniscalco, GT; Morra, VB; Russo, CV; Saccà, F; Signoriello, E; Sinisi, L1
Castañeda-Cardona, C; Cuestas, JA; Hernández, F; Lasalvia, P; Rosselli, D1
Dandu, N; Hjorth, M; Mellergård, J1
Bergmann, A; Braune, S; Heer, Y; Jules, E; Lionetto, F; Stühler, E; van Hövell, P; Westermann, C1
Frequin, STFM; Hoogervorst, ELJ; Jeung, L; Smits, LMG; van Oosten, BW1
Filippi, M; Moiola, L; Pagani, E; Preziosa, P; Rocca, MA; Rodegher, M; Storelli, L1
Carneseca, EC; Julian, GS; Rigolon, J; Rosim, RP1
Harirchian, MH; Kamali, H; Poursadeghfard, M; Sadeghipour, A; Sarraf, P1
Asseyer, S; Bäcker-Koduah, P; Berge, T; Boffa, G; Campi, C; Cellerino, M; Harbo, HF; Høgestøl, E; Inglese, M; Ivaldi, F; Kerlero de Rosbo, N; Lapucci, C; Laroni, A; Novi, G; Palmeri, S; Pardini, M; Paul, F; Piana, M; Rotta, G; Sbragia, E; Uccelli, A; Vila, G; Villoslada, P1
Álvarez-Cermeño, JC; Ayuso, T; Contreras Martín, Y; Durán, C; Herrera Navarro, N; Martínez-Yelamos, S; Meca-Lallana, J; Meca-Lallana, V; Millán Pascual, J; Pérez Sempere, A; Ricart, J; Romero Sevilla, R1
Annovazzi, P; Baroncini, D; Barone, S; Barrilà, C; Binello, E; Bonavita, S; Carmisciano, L; Cerqua, R; Clerico, M; Cocco, E; Cordioli, C; Di Sapio, A; Frau, J; Frigeni, B; Grasso, R; Gutierrez, LP; Ippolito, D; La Gioia, S; Landi, D; Lanzillo, R; Laroni, A; Lavorgna, L; Maniscalco, GT; Mataluni, G; Perini, P; Pontecorvo, S; Rasia, S; Repice, A; Russo, CV; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Stromillo, ML; Torri Clerici, V; Turano, G; Zarbo, IR1
Albanese, M; Barbano, L; De Geronimo, D; Giorno, P; Landi, D; Marfia, GA; Parisi, V; Parravano, M; Ziccardi, L1
Ara, JR; Barrero, F; Forero, L; Izquierdo, G; Mallada-Frechin, J; Martínez-Ginés, ML; Marzo, ME; Meca-Lallana, J; Meca-Lallana, V; Moreno, MJ; Oreja-Guevara, C; Sánchez-Vera, I1
Berger, T; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F4
Bertolotto, A; Capobianco, M; Carotenuto, A; Colombo, D; Comi, G; Iaffaldano, P; Morra, VB; Nica, M; Pozzilli, C; Prosperini, L; Rizzoli, S; Sangalli, F; Trojano, M1
Aktas, O; Bielor, C; Hartung, HP; Kremer, D; MacKenzie, C; Müller, AK; Weyers, V; Wienemann, T1
Bussone, G; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Pourcher, V; Roux, T1
Goh, LY; Harvey, JP; Jackson, TL; Kirthi, V; Silber, E1
Adam, EH; Bauer, B; Foerch, C; Friedauer, L; Wolf, T1
Valencia-Sanchez, C; Wingerchuk, DM1
Aoki, R; Hirano, S; Kuwabara, S; Masuda, H; Mori, M; Ohtani, R; Uchida, T; Uzawa, A1
Bürkner, PC; Hartung, HP; Holling, H; Johnen, A; Landmeyer, NC; Meuth, SG; Ruck, T; Wiendl, H1
Bowen, JD; Brink, J; Brown, TR; Lucassen, EB; Repovic, P; Smoot, K; Wundes, A1
Azimi, AR; Nourbakhsh, B; Safavi, F1
Benkert, P; Décard, B; Derfuss, T; Hänni, P; Kappos, L; Kuhle, J; Lienert, C; Lorscheider, J; Moser, A; von Wyl, V; Yaldizli, Ö1
Diaz, V; Guevara, C; Naves, R; Rosas, CS; Villa, E1
Costa, FG; Hung, CT; Hung, NA; Rosenberg, ME1
Chen, W; Maiberger, M; Maloni, H; Mukharesh, L; Wallin, M1
Badolato, R; Capra, R; Chiarini, M; Giacomelli, M; Imberti, L; Moratto, D; Paghera, S; Rossi, N1
Gomez-Mayordomo, V; González-García, N; Matías-Guiu, J; Matías-Guiu, JA; Montero-Escribano, P; Porta-Etessam, J1
Eker, S; Gümüş, H; Karaküçük, Y1
Brinker, A; Croteau, D; Kortepeter, CM; Tobenkin, A1
Cárcamo, C; Ciampi, E; Pelayo, C; Reyes, A; Soler, B; Uribe-San-Martín, R; Vergara, E1
Cascione, M; Cree, BAC; Hunter, SF; Meng, X; Schofield, L; Tenenbaum, N; Thomas, FP; Weiss, JL; Williams, IM1
Carletti, S; Cerqua, R; Danni, M; Lattanzi, S; Rocchi, C; Silvestrini, M; Taffi, R1
Mukharesh, L; Rothstein, TL1
Acar, NP; Esendagli, G; Goksen, S; Karabudak, R; Karaosmanoglu, B; Ozbay, FG; Ozkazanc, D; Sayat, G; Taskiran, EZ; Tuncer, A1
Alvarez, E; Corboy, JR; Nair, K; Sillau, S; Vollmer, BL; Vollmer, T1
Chouette, I; Durand, B; Lamy, F; Meite, M; Mekies, C; Papeix, C; Rerat, K; Tourbah, A; Tourniaire, P1
Aschmann, HE; Kesselring, J; Puhan, MA; Spanu, A1
Davydovskaya, MV; Kurguzova, DO; Luchinina, EV; Serebrova, SY; Shelekhova, TV; Zhuravleva, MV1
Amiri, MRM; Baghbanian, SM1
Benkert, P; Derfuss, T; Hänni, P; Kappos, L; Kuhle, J; Lienert, C; Lorscheider, J; Yaldizli, Ö2
Clarelli, F; Colombo, B; Comi, G; Esposito, F; Ferrè, L; Filippi, M; Martinelli, V; Mogavero, A; Moiola, L; Sangalli, F1
Batista, S; Cerqueira, JJ; Correia de Sá, J; Correia, AS; Costa, A; Ferreira, J; Martins Silva, A; Mendonça, MT; Nunes, CC; Pinheiro, J; Salgado, V; Sequeira, J; Sousa, L1
Avasarala, J1
Boffa, G; Bonavita, S; Cellerino, M; Ferrero, M; Inglese, M1
Comi, G; Dalla Costa, G; Moiola, L1
Abdoli Shadbad, M; Ayromlou, H; Baghbani, E; Baradaran, B; Jigari-Asl, F; Khamiriyan, M; Khaze Shahgoli, V; Noorolyai, S; Rahmani, S; Safaralizadeh, R; Shanehbandi, D1
Adlard, N; Khurana, V; Mah, JK; Nakhaipour, HR; Pohl, D; Schecter, R; Sébire, G; Vudumula, U1
Arnold, DL; Butzkueven, H; Campbell, N; Filippi, M; Geurts, JJ; Ho, PR; Jeffery, D; Licata, S; Santra, S1
Fernández Bargiela, N; Giménez Arufe, V; Martín Herranz, I; Mondelo García, C; Vizoso Hermida, JR1
Filippi, M; Moiola, L; Pagani, E; Preziosa, P; Rocca, MA; Rodegher, M1
Bryll, A; Drabik, L; Karcz, P; Kolasinska, J; Kolasinska, M; Marona, M; Popiela, T; Skladzien, J; Slowik, A; Szaleniec, J; Wnuk, M; Ziekiewicz, M1
Conway, DS; Nakamura, K; Oh, SH; Ontaneda, D; Planchon, SM; Sakaie, K; Thompson, NR1
Derfuss, T; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Lorscheider, J; Oechtering, J1
Alonso, R; Balbuena, ME; Bizzo, AL; Carnero Contentti, E; Carrá, A; Cohen, L; Correale, J; Cristiano, E; Deri, N; Eizaguirre, MB; Garcea, O; Lazaro, L; Liguori, NF; Lopez, P; Man, F; Miguez, J; Pappolla, A; Patrucco, L; Pettinichi, JP; Pita, C; Rojas, JI; Silva, BA; Tkachuk, V1
Airas, L; Bezukladova, S; Matilainen, M; Rissanen, E; Saraste, M; Saunavaara, V; Sucksdorff, M1
Bao, F; Bernitsas, E; Kopinsky, H; Lichtman-Mikol, S; Razmjou, S; Santiago-Martinez, C; Yarraguntla, K1
Alroughani, R; Ampapa, R; Barnett, M; Bergamaschi, R; Boz, C; Butler, E; Butzkueven, H; Cristiano, E; Csepany, T; Diouf, I; Duquette, P; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Hupperts, R; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kermode, A; Lechner-Scott, J; Lugaresi, A; Malpas, C; McCombe, P; Moore, F; Olascoaga, J; Piroska, I; Prat, A; Prevost, J; Pucci, E; Ramo-Tello, C; Rozsa, C; Saladino, ML; Sanchez-Menoyo, JL; Sas, A; Sharmin, S; Shaw, C; Shaygannejad, V; Shuey, N; Simo, M; Singhal, B; Sirbu, CA; Skibina, O; Slee, M; Sola, P; Spelman, T; Spitaleri, D; Taylor, B; Terzi, M; Trojano, M; van der Walt, A; Van Pesch, V; Vucic, S1
Abraham, MJ; Acevedo, JAG; Fang, X; Gogia, B; Rai, PK; Thottempudi, N; Villarreal, JV1
Harrer, A; Moser, T; Pilz, G; Radlberger, RF; Sakic, I; Wipfler, P1
Al Malik, YM1
Guidetti, D; Immovilli, P; Morelli, N; Rota, E1
Ferilli, MAN; Papetti, L; Valeriani, M1
Filippi, M; Meani, A; Moiola, L; Preziosa, P; Rocca, MA; Rodegher, M; Storelli, L1
Ciftci, O; Ekmekyapar, T; Ozcan, C1
Archer, RL; Baltz, BP; Chacko, JA; Chacko, JG; Stout, PW; Strati, P1
Demir, R; Yevgi, R1
Delgado, S; Hernandez, J; Rammohan, K; Tornes, L1
Eadie, MJ; Goudarzi, MH; Hollingworth, SA1
Abrahamowicz, AA; Child, DD; Chow, EJ; Dao, A; Garvin, K; Gill, SK; Morrison, ED; Rogers, DM1
Berger, J; Bourdin, A; Bugnon, O; Locatelli, I; Schluep, M; Schneider, MP1
Capone, F; Di Lazzaro, V; Ferraro, E; Motolese, F1
Lanzillo, R; Petruzzo, M1
Du Pasquier, R; Le Goff, G; Pantazou, V; Pot, C; Théaudin, M2
Anwar-Hashim, Z; Aslanyan, A; Mihalova, T; Siripurapu, R1
Caputo, F; Guerra, T; Iaffaldano, P; Orlando, B; Paolicelli, D; Trojano, M1
Bertolotto, A; Capobianco, M; Malucchi, S1
Ahmed, SF; Akkawi, N; Al Atat, R; Al Otaibi, H; Al-Aasmi, A; AlKawi, Z; Alroughani, R; Alsaadi, T; El Fadally, H; Hassan, A; Inshasi, J; Koussa, S; Mujtaba, A; Riachi, N; Zakaria, M1
Amidei, A; Pasquali, L; Siciliano, G1
Borriello, G; Pozzilli, C1
Amato, MP; Derfuss, T; Fonderico, M; Hemmer, B; Portaccio, E; Selmaj, K; Stankoff, B; Tintorè, M1
Cohen, JA; Cree, BA; Kappos, L; Laflamme, AK; Leppert, D; Piani Meier, D; Reder, AT; Ritter, S; Silva, D; Tomic, D1
Beckmann, Y; Türe, S; Uzunköprü, C1
Baroncini, D; Bonavita, S; Caleri, F; Carotenuto, A; Cepparulo, S; Curti, E; Frau, J; Landi, D; Lanzillo, R; Lus, G; Maniscalco, GT; Marfia, GA; Nicoletti, CG; Nociti, V; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Zaffaroni, M1
Abulaban, A; Aggad, H; Al Bunyan, R; Al Jumah, M; Al Malik, Y; AlKhawajah, M; Almejally, M; Alnajashi, H; Alshamrani, F; Bohlega, S; Cupler, EJ; ElBoghdady, A; Makkawi, S; Qureshi, S; Shami, S1
Jacobs, D; Pham Nguyen, TP; Thibault, D; Willis, AW1
Filippi, M; Moiola, L; Zanetta, C1
Zaffaroni, M1
Assouad, R; Boudot de la Motte, M; Depaz, R; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Roux, T1
Baalbaki, MM; Bou Reslan, SW; Darwish, H; El Ayoubi, NK; Khoury, SJ1
Afzali, AM; Aly, L; Bauer, IJ; Beltrán, E; Buchholz, VR; Busch, DH; Domínguez Moreno, H; Dornmair, K; Franzenburg, S; Garg, G; Gasperi, C; Gerdes, LA; Grassmann, S; Hemmer, B; Hiltensperger, M; Jarosch, S; Kant, R; Kawakami, N; Kenet, S; Knier, B; Korn, T; Kümpfel, T; Lepennetier, G; Misgeld, T; Muschaweckh, A; Öllinger, R; Rad, R; Schober, K; Sie, C; Tyystjärvi, S1
Al-Khedr, A; Alroughani, R; Andersen, JB; Berger, E; Bourre, B; Boz, C; Bramow, S; Butzkueven, H; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Ciron, J; Clavelou, P; Csepany, T; Debouverie, M; Defer, G; Duquette, P; Edan, G; Eichau, S; Ferraro, D; Frederiksen, JL; Girard, M; Gout, O; Grammond, P; Grand Maison, F; Granella, F; Hankiewicz, K; Havrdova, EK; Heinzlef, O; Hilt Christensen, CC; Horakova, D; Izquierdo, G; Jensen, MB; Kalincik, T; Karabudak, R; Koch-Henriksen, N; Labauge, P; Labeyrie, C; Laplaud, DA; Lebrun, C; Lechner-Scott, J; Lefort, M; Leray, E; Lugaresi, A; Magyari, M; Maillart, E; Marousset, A; Mathiesen, HK; Maubeuge, N; McCombe, P; Montcuquet, A; Moreau, T; Nifle, C; Onofrj, M; Ozakbas, S; Patry, I; Patti, F; Pelletier, J; Pottier, C; Prat, A; Prevost, J; Rasmussen, PV; Ruet, A; Schreiber, KI; Sellebjerg, F; Sèze, JD; Sharmin, S; Shaygannejad, V; Skibina, O; Slee, M; Sola, P; Solaro, C; Spitaleri, D; Stankoff, B; Sørensen, PS; Terzi, M; Thouvenot, E; Trojano, M; Turkoglu, R; Vucic, S; Vukusic, S; Wahab, A; Wijmeersch, BV; Yamout, B; Zephir, H1
Espinosa-Rosso, R; Gil-Bernal, R; Gómez-Gómez, C; González-Caballero, JL1
Boffa, G; Cellerino, M; Cocco, E; Fenu, G; Frau, J; Fronza, M; Inglese, M; Landi, D; Mancuso, E; Marfia, GA; Nicoletti, CG; Ponzano, M; Ricchiuto, ME; Signori, A1
Bigaut, K; Cohen, M; de Seze, J; Durand-Dubief, F; Lebrun-Frenay, C; Maillart, E; Planque, E; Zephir, H1
Clarelli, F; Comi, G; Esposito, F; Ferrè, L; Filippi, M; Martinelli Boneschi, F; Martinelli, V; Mascia, E; Moiola, L; Ottoboni, L; Provero, P; Santoro, S; Sferruzza, G; Sorosina, M1
Baba, C; Ozakbas, S; Piri Cinar, B; Sagici, O; Yigit, P1
Alvarez-González, C; Bellmann-Strobl, J; Dörr, J; Infante-Duarte, C; Paul, F; Schlickeiser, S; Schroeder-Castagno, M; Schwichtenberg, SC; Siebert, N; Wernecke, KD; Wisgalla, A1
Englund, S; Fang, F; Frisell, T; Longinetti, E; Piehl, F; Reutfors, J1
Brescia Morra, V; Capobianco, M; Cavalla, P; Cellerino, M; Ferraro, D; Guerra, T; Iaffaldano, P; Inglese, M; Lus, G; Malucchi, S; Mirabella, M; Paolicelli, D; Patti, F; Pisano, E; Sola, P; Trojano, M; Vitetta, F; Zaffaroni, M1
Bonifácio, G; Correia, F; Costa, A; Ferro, D; Gonçalves, AI; Guerreiro, RP; Loureiro, JL; Pinheiro, J; Rocha, R; Rodrigues, R; Sá, MJ; Sabença, F; Vale, J1
Adlard, N; Brennan, R; Cameron, C; Dahlke, F; Drudge, C; Haltner, A; Samjoo, IA; Spin, P; Worthington, E1
Bonavita, S; Miele, G; Sparaco, M1
Calabrese, P; Cutter, G; Dahlke, F; Häring, DA; Kappos, L; Langdon, DW; Penner, IK; Tomic, D1
González-Suarez, I; Jorquera Moya, M; Matias-Guiu, JA; Moreno-García, S; Oreja-Guevara, C; Orviz, A; Rodríguez de Antonio, L; Valencia, C; Valle-Arcos, MD1
Butzkueven, H; Havrdova, E; Kalincik, T; Merkel, B; Traboulsee, AL1
Damas, F; Izquierdo, G; Navarro, G; Páramo, MD; Ruiz-Peña, JL1
Alcala-Vicente, C; Bosca-Blasco, I; Casanova-Estruch, B; Coret-Ferrer, F; Gascon-Gimenez, F; Navarre-Gimeno, A; Perez-Miralles, FC1
Dashputre, AA; Kamal, KM; Pawar, G1
Carreón Guarnizo, E; García Vazquez, E; Hernández Clares, R; Meca Lallana, JE; Sánchez Pedreño, P1
Avasarala, J; Jain, S; Urrea-Mendoza, E1
Debs, R; Delvaux, V; Lubetzki, C; Maillart, E; Masingue, M; Papeix, C; Vidal, JS1
Aslam, T; Jasani, KM; Rog, D; Sharaf, N1
Adlard, N; Kusel, J; Montgomery, SM; Nicholas, R1
Dick, HB; Elling, M; Kakkassery, V; Kleiter, I; Rehrmann, J; Schelenz, D; Schöllhammer, J1
Al-Hussain, F; Al-Salloum, N; Alazwary, N; Daif, A; Howaidi, S; Saeedi, J1
Kinoshita, M; Tanaka, K; Tanaka, M1
Achiron, A; Alroughani, R; Aref, H; Bijarnia, M; Cooke, K; Harb, M; Inshasi, J; Yuksel, O1
Bramanti, P; Guarnera, C; Mazzon, E1
Balk, LJ; Dekker, I; Killestein, J; Leurs, CE; Rispens, T; Uitdehaag, BM; van Kempen, ZL; Wattjes, MP1
Proschmann, U; Thomas, K; Ziemssen, T1
Barnett, M; Butler, E; Butzkueven, H; Duquette, P; Fabis-Pedrini, M; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Jokubaitis, V; Kalincik, T; Kermode, A; Lechner-Scott, J; Lugaresi, A; McCombe, P; Prat, A; Prevost, J; Shaw, C; Slee, M; Sola, P; Solaro, C; Spelman, T; Terzi, M; Trojano, M1
Havla, J; Hohlfeld, R; Kümpfel, T; Meinl, I1
Aburahma, A; Al Hadidi, S; Alkotob, ML; Elounais, F1
Calvi, A; Carandini, T; De Riz, M; Galimberti, D; Ghezzi, L; Lecchi, E; Maurichi, A; Pellegrinelli, A; Pietroboni, A; Scarioni, M; Scarpini, E1
Haegele-Link, S; Humm, A; Hundsberger, T; Kaegi, G; Mueller, SK; Sauter, R; Tettenborn, BE; Vehoff, J1
Fernández, Ó1
Amato, MP; Bartezaghi, M; Bergh, FT; Centonze, D; Comi, G; Filippi, M; Gallo, P; Mattioli, FC; Patti, F; Pozzilli, C; Rocca, MA; Saccà, F; Turrini, R1
Di Lecce, V; Direnzo, V; Iaffaldano, A; Iaffaldano, P; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S1
Appel, S; Kucuk, N; Milo, R; Nitsan, Z; Osherov, M; Tichmanovich, N1
Aghayerashti, M; Badihian, S; Fazeli, M; Hasheminia, J; Maghzi, H; Shaygannejad, V; Zandi-Esfahan, S1
Akbulak, RÖ; Heesen, C; Hoffmann, BA; Pinnschmidt, HO; Rosenkranz, SC; Schaeffer, BN; Willems, S1
Adamczyk, B; Adamczyk-Sowa, M; Kasperczyk, S; Wawrzyniak, S1
Bakshi, R; Chitnis, T; Chu, R; Dupuy, SL; Healy, BC; Khalid, F; Kim, G; Tauhid, S; Tummala, S; Weiner, HL; Yousuf, F1
Chataway, J; Doshi, A1
Hongell, K; Meier, DP; Ritter, S; Silva, DG; Soilu-Hänninen, M1
Allali, G; Armand, S; Assal, F; Herrmann, FR; Laidet, M; Lalive, PH; Lingenberg, A1
Calkwood, J; Khan, N; Korn, JR; Lathi, E; Medin, J; Silva, D; Silversteen, J; Weinstock-Guttman, B; Zivadinov, R1
Boremalm, M; Frisell, T; Granqvist, M; Piehl, F; Poorghobad, A; Salzer, J; Svenningsson, A1
Achiron, A; Gurevich, M; Stone, E; Waknin, R1
Eriksson, I; Komen, J; Malmström, RE; Piehl, F; von Euler, M; Wettermark, B1
Bachmann, V; Baumann, A; Czaplinski, A; Findling, O; Kamm, CP; Lalive, PH; Perriard, G; Pless, ML; Roth, S; Zecca, C1
Buttari, F; Centonze, D; Di Iorio, G; Landi, D; Lus, G; Marfia, GA; Monteleone, F; Nicoletti, CG; Saccà, F; Sica, F; Signoriello, E1
Navardi, S; Sahraian, MA1
Annunziata, P; Capozzoli, M; Fruschelli, M; Gelmi, MC; Masi, G1
Fukazawa, T; Kinoshita, M; Koda, T; Kumanogoh, A; Miyazaki, Y; Mochizuki, H; Nakatsuji, Y; Namba, A; Niino, M; Okuno, T; Shimizu, M; Sugimoto, T; Takata, K; Yamashita, K1
Chisari, CG; D'Amico, E; Lo Fermo, S; Patti, F; Zanghì, A; Zappia, M1
Gaetano, L; Häring, DA; Kappos, L; Mueller-Lenke, N; Radue, EW; Sprenger, T; Thakur, A; Tomic, D1
Limmroth, V; Ziemssen, T1
Cramer, SP; Frederiksen, JL; Galea, I; Larsson, HBW; Simonsen, HJ; Varatharaj, A1
Duchesneau, E; Gao, W; Herrera, V; Johnson, K; Kantor, D; Koo, V; Li, N; Signorovitch, J; Vieira, MC1
Afshari, D; Ansarian, A; Bostani, A; Moghadasi, AN; Moradian, N; Ouspid, E; Razazian, N; Sariaslani, P1
Kalincik, T1
Bayas, A; Doerck, S; Frank, B; Gerbershagen, K; Gold, R; Hellwig, K; Huhn, K; Kallmann, B; Kleinschnitz, C; Kleiter, I; Lee, DH; Limmroth, V; Linker, RA; Mäurer, M; Meuth, S; Rieckmann, P; Ruck, T1
Giacomini, PS1
Bandini, F; Cavalla, P; Giordana, MT; Laroni, A; Mancardi, G; Uccelli, A; Vercellino, M1
Benedetti, MD; Bozzetti, S; Gajofatto, A; Gobbin, F; Marangi, A; Mocella, S; Pea, M; Turatti, M1
Aboulwafa, M; Clarelli, F; Comi, G; Dalla Costa, G; Esposito, F; Ferre', L; Filippi, M; Martinelli Boneschi, F; Martinelli, V; Mascia, E; Moiola, L; Radaelli, M; Rocca, MA; Sangalli, F; Sferruzza, G1
Annovazzi, P; Baroncini, D; Cocco, E; Cordioli, C; Fenu, G; Forci, B; Frau, J; Frigeni, B; Grasso, R; La Gioia, S; Lanzillo, R; Maniscalco, GT; Rasia, S; Realmuto, S; Rossi, S; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Stromillo, ML1
Bellantonio, P; Bianco, A; Buscarinu, MC; Buttari, F; Centonze, D; Cortese, A; De Giglio, L; Fantozzi, R; Ferraro, E; Fornasiero, A; Francia, A; Galgani, S; Gasperini, C; Haggiag, S; Lucchini, M; Marfia, GA; Millefiorini, E; Mirabella, M; Nociti, V; Pontecorvo, S; Pozzilli, C; Prosperini, L; Ruggieri, S; Salvetti, M; Sgarlata, E1
Frequin, STFM; Heisen, M; Piena, MA; Uitdehaag, BMJ; Wingerden, JV; Wormhoudt, LW1
Adlard, NE; Kroes, MA; Montgomery, SM; Noon, KM1
Bajrami, A; Calabrese, M; Castellaro, M; Monaco, S; Montemezzi, S; Pitteri, M; Pizzini, F; Romualdi, C1
Connolly, A; Grandi, V; Palmer, R; Stefanato, CM; Weir, A; Whittaker, S1
Fitzner, B; Hecker, M; Koczan, D; Zettl, UK1
Barrero, F; En Representacion de Los Investigadores Del Estudio Ms Next, ERLIDEMN; Garcia, E; Mallada-Frechin, J; Martinez-Gines, ML; Marzo-Sola, ME; Meca-Lallana, V; Ricart, J1
Danielsen, AC; Dominguez-Villar, M; Guarnaccia, J; Hafler, DA; Raddassi, K1
Arnold, DL; Banwell, B; Bar-Or, A; Brück, W; Chen, Y; Chitnis, T; Gärtner, J; Ghezzi, A; Giovannoni, G; Greenberg, B; Krupp, L; Merschhemke, M; Putzki, N; Rostásy, K; Stites, T; Tardieu, M; Waubant, E; Wolinsky, JS1
De Stefano, N; Giovannoni, G; Haering, DA; Kappos, L; Langdon, D; Piani-Meier, D; Sormani, MP; Tomic, D1
Bergmann, A; Braune, S; Freudensprung, U; Grimm, S; Hyde, R; Pellegrini, F; van Hövell, P1
Friede, T; Häring, DA; Schmidli, H1
Ioka, T; Iwazu, K; Iwazu, Y; Kusano, E; Muto, S; Nagata, D; Watanabe, Y1
Macaron, G; Ontaneda, D1
Corbett, A; Kermode, AG; Reddel, SW; Triplett, J1
Aufenberg, C; Doerck, S; Eienbroeker, C; Haas, J; Kleinschnitz, C; Klotz, L; Lang, M; Lee, DH; Limmroth, V; Linker, RA; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Pul, R; Ruck, T; Schmidt, R; Straeten, FA; Straeten, V; Tackenberg, B; Wiendl, H; Wieshuber, M; Wildemann, B; Windhagen, S1
Gurses, KM; Karabudak, R; Kocyigit, D; Tokgozoglu, L; Yalcin, MU1
Bajer-Kornek, B; Berger, T; Deisenhammer, F; Walter, E1
Emamnejad, R; Izad, M; Laribi, B; Marzban, M; Sadaghiani, S; Sahraian, MA; Shekarabi, M1
Borhanihaghighi, A; Izadi, S; Keshavarz, K; Ravangard, R; Rezaee, M1
Aramideh Khouy, R; Bokharaei-Salim, F; Esghaei, M; Etemadifar, M; Karampoor, S; Keyvani, H; Monavari, SH; Taghinezhad, S1
Alroughani, R; Ampapa, R; Bergamaschi, R; Boz, C; Butler, E; Butzkueven, H; Duquette, P; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Lugaresi, A; McCombe, PA; Onofrj, M; Ozakbas, S; Pesch, VV; Prat, A; Prevost, J; Pucci, E; Ramo-Tello, C; Sánchez-Menoyo, JL; Shaygannejad, V; Slee, M; Sola, P; Solaro, C; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Turkoglu, R; Van Wijmeersch, B; Vucic, S; Yamout, B1
Duquette, P; Haddad, P; Mouallif, S; Nakhaipour, HR; Schecter, R; Yeung, M1
Du Pasquier, R; Lalive, PH; Roth, S1
Berger, JR; Cree, BA; Dong, VM; Greenberg, B; Hemmer, B; Merschhemke, M; Ward, BJ1
Alroughani, R; Bergamaschi, R; Brown, JWL; Butzkueven, H; Coles, A; Duquette, P; Ferraro, D; Flechter, S; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Harding, K; Havrdova, E; Horakova, D; Hupperts, R; Hutchinson, M; Izquierdo, G; Jokubaitis, V; Jones, J; Kalincik, T; Lechner-Scott, J; Lugaresi, A; McCombe, P; McGuigan, C; Pearson, OR; Prat, A; Pucci, E; Rice, C; Robertson, N; Scolding, N; Shaygannejad, V; Slee, M; Sola, P; Terzi, M; Trojano, M; Van Pesch, V; Wilkins, A; Willis, M; Ziemssen, T1
Axelsson, M; Dubuisson, N; Giovannoni, G; Gnanapavan, S; Lycke, J; Malmeström, C; Novakova, L1
Alcalá, C; Casanova, B; Domínguez, JA; Gascón, F; Gil-Perotín, S; Pérez-Miralles, F1
AlOrainy, IA; AlTahan, AM; AlTahan, H; Berger, T1
Chirikov, V; Cornelio, N; Giambrone, C; Hashemi, L; Joshi, N; Ma, I; Patel, D; Smith, A1
Bensimon, AG; Fox, E; Herrera, V; Johnson, K; Peeples, M; Signorovitch, J; Vieira, MC1
Barro, C; Dahlke, F; Haering, DA; Kappos, L; Kropshofer, H; Kuhle, J; Kundu, U; Leppert, D; Meinert, R; Tomic, D1
Axelsson, M; Boremalm, M; Frisell, T; Juto, A; Lycke, J; Novakova, L; Piehl, F; Salzer, J; Svenningsson, A1
Harding, K; Hrastelj, J; Joseph, F; Pickersgill, T; Rimmer, A; Robertson, N; Tallantyre, E; Tomassini, V; Wardle, M; Williams, O; Willis, M1
Álvarez-Sánchez, N; Carrillo-Vico, A; Cruz-Chamorro, I; Díaz-Sánchez, M; Guerrero, JM; Lardone, PJ1
Berardi, A; Harty, G; Siddiqui, MK; Treharne, C; Wong, SL1
Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P1
Albrecht, H; Cornelissen, C; Couto, CA; Findlay, JA; Haas, J; Klotz, L; Lang, M; Lassek, C; Schmidt, S; Tackenberg, B; Ziemssen, T1
Cave, J; Herrera, V; Hersh, CM; Hua, LH; Ko, JJ; Kusel, J; Lin, F; Morten, P; Varga, S1
Bugnon, O; Mazellier, S; Michiels, JF; Michiels, Y1
Brownlee, WJ; Carroll, A; Chataway, J; John, N1
Bhan, V; Fiander, MDJ; Parks, NE; Stewart, SA1
Hu, F; Li, H; Li, K; Zhang, Y1
Baldi, E; Caniatti, LM; Curti, E; Ferraro, D; Granella, F; Sola, P; Tsantes, E1
Berger, J; Bourdin, A; Bugnon, O; Schluep, M1
Annovazzi, P; Baroncini, D; Bonavita, S; Capobianco, M; Carotenuto, A; Clerico, M; Cocco, E; Fenu, G; Frau, J; Gallo, A; La Gioia, S; Lapucci, C; Laroni, A; Maniscalco, GT; Russo, CV; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP1
Polanco, A; Poveda, JL; Rubio-Rodríguez, D; Rubio-Terrés, C; Torres, C; Trillo, JL1
Blumenfeld-Kan, S; Miller, A; Staun-Ram, E1
Breville, G; Lalive, PH; Lascano, AM; Merkler, D; Roth, S1
Hirano, S; Kojima, K; Kuwabara, S; Masuda, H; Mori, M; Ohtani, R; Uchida, T; Uzawa, A1
Girard, M; Labrie, M; Muccilli, A; Nehme, A; Odier, C; Poppe, AY1
Bartosik-Psujek, H; Bielecki, B; Brola, W; Ciach, A; Czajka, A; Dorobek, M; Glabinski, A; Kapica-Topczewska, K; Kochanowski, J; Kulakowska, A; Kurkowska-Jastrzebska, I; Kurowska, K; Maciagowska-Terela, M; Nojszewska, M; Podlecka-Pietowska, A; Rusek, S; Siger, M; Stasiolek, M; Stepien, A; Tutaj, A; Walczak, A; Wicha, W; Wlodek, A; Zajdel, R; Zakrzewska-Pniewska, B1
Betensky, RA; Chin, P; Eckert, B; Mandel, M; Mercier, F1
Brinkmann, V; Burgener, AV; Gubser, P; Hess, C; Kappos, L; Luster, AD; Mehling, M1
Arakawa, M; Hokari, M; Ishiguro, T; Ishihara, T; Kawachi, I; Nishizawa, M; Okamoto, K; Saji, E; Yanagimura, F; Yokoseki, A1
Fedorova, SI; Iakushina, TI; Kotov, SV; Lizhdvoĭ, VIu1
Eadie, M; Hollingworth, S; Page, A; Walker, K1
Chang, A; Chui, J; Herkes, GK1
Guerrero, M; Roberts, E; Rosen, H; Urbano, M1
Almeida, DR; Belliveau, MJ; Dorrepaal, SJ; Gale, JS; Minuk, A1
Barkhof, F; Cohen, JA; Comi, G; Eckert, B; Francis, G; Häring, DA; Izquierdo, G; Khatri, B; Montalban, X; Pelletier, J1
Amato, MP; Hakiki, B; Pastò, L; Piscolla, E; Portaccio, E; Razzolini, L1
Barbato, LM; Cascione, M; McCague, K; Pestreich, L; Schofield, L; Wynn, D1
Battaglia, F; Brogi, D; Fenoglio, D; Filaci, G; Kalli, F; Mancardi, GL; Parodi, A; Serpero, LD; Uccelli, A1
Campbell, JD; Corboy, JR; McQueen, RB; Miravalle, A; Nair, K; Vollmer, TL1
Singer, BA1
Berenguer-Ruiz, L; Feliu-Rey, E; Sempere, AP1
Bhatti, MT; Freedman, SM; Mahmoud, TH1
Huys, AC; Lalive, PH; Sekoranja, L1
Bergmann, A; Braune, S; Lang, M2
Afazel, S; Harrer, A; Haschke-Becher, E; Kraus, J; Oppermann, K; Pilz, G; Sellner, J; Trinka, E; Wipfler, P1
Balcer, LJ; Calabresi, PA; Cello, KE; Durbin, MK; Harvey, DJ; Keltner, JL; Werner, JS; Winges, KM1
Brosa, M; Crespo, C; García-Ruiz, A; Granell, M; Izquierdo, G1
Borghi, V; Cossarizza, A; De Biasi, S; Federzoni, L; Ferraro, D; Nichelli, PF; Simone, AM; Sola, P; Vitetta, F1
Agarwal, S; Deniz, B; Fox, RJ; Havrdova, E; Hutchinson, M; Kurukulasuriya, NC; Sarda, SP; Siddiqui, MK; Taneja, A1
Bijarnia, M; Comi, G; Gold, R; Gottschalk, R; Kappos, L; Palace, J; Siever, A; Tomic, D; von Rosenstiel, P1
Cremer, M; de Vera, A; Francis, G; Izquierdo, G; Kappos, L; Montalban, X; O'Connor, P; Radue, EW; Sfikas, N; von Rosenstiel, P1
Keane, D; O'Kelly, S; Saiva, L; Voon, V1
Thomas, K; Ziemssen, T1
Louapre, C; Lubetzki, C; Maillart, E; Papeix, C1
Montalban, X; Tur, C1
Hao, Q; Itoyama, Y; Kikuchi, S; Kira, J; Kurosawa, T; Nagato, K; Saida, T; Tsumiyama, I; von Rosenstiel, P; Zhang-Auberson, L1
Weinstock-Guttman, B1
Aoki, M; Bar-Or, A; Fujihara, K; Kuroda, H; Misu, T; Nakashima, I; Nishiyama, S; Sato, DK; Suzuki, C1
Agashivala, N; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; McGuiness, CB; Petrilla, AA; Pradhan, A1
Constantinescu, CS; Tanasescu, R1
Beggiato, E; Broganelli, P; Cavalla, P; Chiavazza, C; Crosasso, P; Masera, S; Mattioda, A; Pinessi, L; Superti, G1
Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Duquette, P; Girard, M; Giuliani, G; Grand'Maison, F; Haartsen, J; Hodgkinson, S; Izquierdo, G; Jokubaitis, VG; Kalincik, T; Lechner-Scott, J; Li, V; Liew, D; Lugaresi, A; Shaw, C; Slee, M; Spitaleri, DL; Trojano, M; Verheul, F1
Giovannoni, G; Naismith, RT1
Ahmed, SF; Al-Hashel, J; Alroughani, R; Behbehani, R2
Agius, MA; Calabresi, PA; Cappiello, L; Goodin, D; Jeffery, D; Kappos, L; Li, B; Lublin, FD; Radue, EW; Rammohan, KW; Reder, AT; Stites, T; Vollmer, T; von Rosenstiel, P1
Sorensen, PS2
El Sankari, S; Marchandise, S; Sindic, C; van Pesch, V1
Erminio, C; La Mantia, L; Marazzi, MR; Prone, V; Protti, A1
Barkhof, F; Cohen, J; de Jong, R; de Vera, A; Francis, G; Sfikas, N1
Baldi, E; Caniatti, L; Curti, E; Ferraro, D; Granella, F; Guareschi, A; Immovilli, P; Montanari, E; Montepietra, S; Motti, L; Pesci, I; Senesi, C; Simone, AM; Sola, P; Tola, MR; Vitetta, F1
Botto, G; Pentimalli, F; Vanoli, E1
Eienbröker, C; Gold, R; Havla, J; Hellwig, K; Hoepner, R; Hohlfeld, R; Kleiter, I; Kümpfel, T; Meinl, I; Tackenberg, B1
Buckle, GJ; Carruthers, RL; Chitnis, T; Healy, BC; Rotstein, DL; Weiner, HL1
Daniels, JM; Killestein, J; Looysen, EE; van Rossum, JA1
Halank, M; Schrötter, H; Thomas, K; Ziemssen, T1
Centonze, D; Germani, G; Lauretti, B; Macchiarulo, G; Marfia, GA; Motta, C; Rocchi, C; Rossi, S; Studer, V1
Bertolotto, A; Capobianco, M; di Sapio, A; Malentacchi, M; Malucchi, S; Matta, M; Sperli, F1
Falato, E; Filippi, MM; Ghazaryan, A; Landi, D; Mulas, D; Pasqualetti, P; Pellegrino, G; Rossini, PM; Vollaro, S1
Bajusz, I; Chiquete, E; Correale, J; Frider, N; Milojevic, S1
Cruz, VT; Fonseca, J1
Sanford, M1
Damoiseaux, J; Hupperts, R; Koeman, E; Muris, AH; Rolf, L1
Carrithers, MD1
Benedetti, MD; Bianchi, MR; Deotto, L; Gajofatto, A1
Chinea Martinez, AR; Correale, J; Coyle, PK; Meng, X; Tenenbaum, N1
Bridel, C; Lalive, PH1
Barcella, V; Comi, G; Ferrè, L; Martinelli, V; Moiola, L; Radaelli, M; Sangalli, F1
Comi, G; Dahlke, F; Gold, R; Kappos, L; Sinha, A; Tomic, D; von Rosenstiel, P1
McDonald, EA; Sedal, L; Wilson, IB1
Biotti, D; Brassat, D; Bucciarelli, F; Bucur, C; Clanet, M; Gaina, J; Martin-Blondel, G; Peaureaux, D; Pignolet, B1
Tang, Y1
Hay, JW; Niu, X; Zhang, X1
Broux, B; Claes, N; Dhaeze, T; Fraussen, J; Hellings, N; Hupperts, R; Somers, V; Stinissen, P; Van Wijmeersch, B1
Bertoli, D; Caimi, L; Capra, R; Chiarini, M; Imberti, L; Rasia, S; Serana, F; Sottini, A1
Batocchi, AP; Bianco, A; De Fino, C; Fetta, A; Frisullo, G; Marti, A; Mirabella, M; Nociti, V; Patanella, AK; Plantone, D; Rossini, PM1
Bergvall, N; Cutter, G; Giovannoni, G; Nixon, R; Sfikas, N; Tomic, D1
Meyer, K; O'Day, K; Stafkey-Mailey, D; Watson, C1
Agashivala, N; Barbato, L; Calkwood, J; Crayton, H; Cree, B; Edwards, K; Hashmonay, R; Kantor, D; McCague, K; Steingo, B; Tenenbaum, N1
Corona, T; Flores, J; Jung, H; Rito, Y; Torres, G; Treviño-Frenk, I1
Thomas, RH; Wakefield, RA1
Chin, PS; Cutter, G; Hashmonay, R; Meng, X; Zahur Islam, M1
Alroughani, R; Barnett, M; Bergamaschi, R; Boz, C; Butzkueven, H; Csepany, T; Duquette, P; Fernandez-Bolanos, R; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Izquierdo, G; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Lugaresi, A; McCombe, P; Oreja-Guevara, C; Pucci, E; Rozsa, C; Rum, G; Sanchez-Menoyo, J; Simo, M; Slee, M; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Verheul, F1
Haas, J; Jarius, S; Kieseier, BC; Korporal-Kunke, M; Schwarz, A; Wiendl, H; Wildemann, B1
Chin, P; De Stefano, N; Francis, G; Kappos, L; Radue, EW; Sormani, MP; Sprenger, T1
Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE1
Francis, G; Hohlfeld, R; Kappos, L; O'Connor, P; Polman, C; Radue, EW; Ritter, S; Schlosshauer, R; Selmaj, K; von Rosenstiel, P; Zhang-Auberson, L1
Chen, Y; Dahlke, F; Disanto, G; Francis, G; Giovannoni, G; Kappos, L; Kuhle, J; Lorscheider, J; Radue, EW; Shrinivasan, A; Stites, T1
Czaplinski, A; Ramseier, SP; Roth, S1
Baumgartner, A; Berger, B; Farenkopf, U; Luetzen, N; Mader, I; Rauer, S; Stich, O1
Cocco, E; Coghe, GC; Fenu, G; Frau, J; Lorefice, L; Marrosu, MG1
Fox, RJ1
Jelcic, I; Linnebank, M; Martin, R; Pfender, N; Schwarz, U1
Coote, M; Gaskin, JC1
Bermel, RA; Hashmonay, R; Kantor, D; Meng, X; Randhawa, S; Sfikas, N; von Rosenstiel, P1
Butzkueven, H; Comi, G; Dahlke, F; Derfuss, T; Giovannoni, G; Gottschalk, R; Griffiths, S; Hartung, HP; Kappos, L; Montalban, X; Mueller-Lenke, N; Naegelin, Y; Radue, EW; Sprenger, T; Tomic, D; von Rosenstiel, P; Wiendl, H; Zhang, Y1
Cavarretta, R; Di Rienzo, M; Ferratini, M; Racca, V; Rovaris, M; Toccafondi, A; Vaini, E3
Adlard, N; Bergvall, N; Griffiths, MJ; Maruszczak, MJ; Montgomery, SM1
Cornelissen, C; Kern, R; Ziemssen, T2
Hartikainen, JE; Hartikainen, P; Laitinen, T; Laitinen, TM; Simula, S; Tarkiainen, T2
Deppe, M; Eveslage, M; Gross, CC; Grützke, B; Kirstein, L; Klotz, L; Meuth, SG; Posevitz-Fejfar, A; Schneider-Hohendorf, T; Schwab, N; Wiendl, H1
Barkhof, F; Cohen, JA; Comi, G; Hartung, HP; Kappos, L; Khatri, B; Montalban, X; Pelletier, J; Ritter, S; Stites, T; Tomic, D; von Rosenstiel, P1
Gábor, L1
Bergvall, NK; Derfuss, T; Sfikas, N; Tomic, DL1
Alvarenga, R; Cruz, A; Frider, N; Ordoñez-Boschetti, L; Rey, R; Reynolds, T; Sinha, A1
Bonitto, JG; Correale, J; Flores, J; Oliveira, EM; Rodríguez, CC1
Khoury, SJ; Sawaya, RA; Yamout, BI; Zeineddine, MM1
Alroughani, R; Amato, MP; Barnett, M; Bergamaschi, R; Boz, C; Butzkueven, H; Cristiano, E; Duquette, P; Fernandez-Bolaños, R; Fiol, M; Girard, M; Grammond, P; Grand'Maison, F; Gray, O; Havrdova, E; Horakova, D; Hupperts, R; Iuliano, G; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kappos, L; Kister, I; Lechner-Scott, J; Lugaresi, A; Moore, F; Oreja-Guevara, C; Petersen, T; Petkovska-Boskova, T; Pucci, E; Saladino, ML; Shaw, C; Shuey, N; Slee, M; Spelman, T; Terzi, M; Trojano, M; Van Pesch, V; Verheul, F; Warrender-Sparkes, M; Young, C1
Akay, EM; Cohen, SN; Evangelou, N; Samaraweera, AP1
Barbato, L; Burch, G; Crayton, H; Edwards, K; Fox, E; Huffman, C; Hunter, SF; Kim, E; LaGanke, C; McCague, K; Pestreich, L; Wynn, DR1
Agashivala, N; Agius, M; Barbato, L; Cascione, M; Freedman, MS; Goldstick, LP; Gudesblatt, M; Hashmonay, R; Hughes, B; Kantor, D; McCague, K; Schofield, L1
Cohen, JA; Collins, W; DiMarco, JP; Kappos, L; O'Connor, P; Reder, AT; Tang, D; Zhang-Auberson, L1
Berlit, P; Herold, M; Kraemer, M; Weber, R1
Antel, J; Comi, G; Cremer, M; de Vera, A; Kappos, L; Montalban, X; O'Connor, P; Sfikas, N; von Rosenstiel, P1
Aktas, O; Finis, D; Geerling, G; Guthoff, R; Harmel, J; Hartung, HP; Ringelstein, M; Schröder, K1
Bakshi, R; Häring, DA1
Cerqua, R; Danni, M; Lattanzi, S; Provinciali, L; Silvestrini, M; Taffi, R1
Amato, MP; Baroncini, D; Bergamaschi, R; Bertolotto, A; Brescia Morra, V; Cavalla, P; Comi, G; Coniglio, G; Corea, F; Ferrò, MT; Ghezzi, A; Granella, F; Guareschi, A; Iaffaldano, P; Iuliano, G; Lepore, V; Lucisano, G; Lugaresi, A; Lus, G; Marrosu, MG; Millefiorini, E; Paolicelli, D; Patti, F; Pozzilli, C; Prosperini, L; Protti, A; Rodegher, M; Saccà, F; Sola, P; Tedeschi, G; Tortorella, C; Trojano, M; Zimatore, GB1
Flor García, A; Gómez Romero, L; Martí Gil, C; Sánchez-Gundín, J1
Camu, W; Di Cantogno, EV; Jeffery, DR; Meier, DP; Radue, EW; Ritter, S1
Haebich, G; Mughal, A; Tofazzal, N1
Cree, BA; De Stefano, N; Freedman, MS; Häring, DA; Kappos, L; Piani Meier, D; Radue, EW; Smith, T; Sormani, MP; Sprenger, T; Tomic, D1
Fox, E; Hawker, K; Jeffery, DR; Rammohan, KW1
Chin, P; Kappos, L; Lublin, F; Radue, EW; Ritter, S; Tomic, D1
Magirr, D; Posch, M; Żebrowska, M1
Aktas, O; Hartung, HP; Ingwersen, J1
Fay, M; Iyer, R; Livingston, T; Mauskopf, J; Sarda, S1
Bowen, JD; Hunter, SF; Reder, AT1
Iljicsov, A; Pál, Z; Simó, M1
Andelova, M; Derfuss, T; Kappos, L; Lindberg, RL; Naegelin, Y; Rasenack, M; Rychen, J; Sprenger, T; Stippich, C1
Baldock, L; Datt, J; Pull, E; Webber, B1
Behle, V; Goebeler, M; Stoevesandt, J; Wobser, M1
Devonshire, V; Freedman, MS; Kremenchutzky, M; Lapierre, Y; O'Connor, P; Schecter, R; Yeung, M1
Guerrero, M; Roberts, E; Urbano, M1
Golzy, N; Pouratian, N; Sharim, J; Tashjian, R1
Cano, CA; Dubey, D; Stüve, O1
Alping, P; Axelsson, M; Björck, A; Fink, K; Frisell, T; Islam-Jakobsson, P; Lycke, J; Malmeström, C; Novakova, L; Piehl, F; Salzer, J; Svenningsson, A1
Batista, S; Correia, I; Ferreira, R; Macário, MC; Marques, IB; Nunes, C; Sousa, L; Sousa, M1
Grau-López, L; Hervás, JV; Mansilla, MJ; Martínez-Cáceres, EM; Quirant-Sánchez, B; Ramo-Tello, C; Teniente-Serra, A1
Filippini, G; Firwana, B; La Mantia, L; Pacchetti, I; Palumbo, R; Tramacere, I1
Crabtree-Hartman, E; Graves, JS; Hatcher, SE; Nourbakhsh, B; Waubant, E1
Fragoso, YD; Sato, HK1
Goodman, AD; Gross, RA; Gyang, TV; Hamel, J; Samkoff, L1
Brew, B; Walker, S1
Agashivala, N; Agius, M; Barbato, L; Chin, P; Cutter, G; Hollander, E; Hunter, SF; McCague, K; Meng, X; Miller, DM1
Annovazzi, PO; Baroncini, D; Colombo, B; Comi, G; Ghezzi, A; Martinelli, V; Minonzio, G; Moiola, L; Rodegher, M; Zaffaroni, M1
De Stefano, N; Häring, D; Meier, DP; Radue, EW; Sormani, MP; Sprenger, T; Tomic, D1
Mihalova, T; Salam, S; Siripurapu, R1
Airas, L; Hovi, A1
Akamatsu, M; Akiyama, H; Hara, D; Hasegawa, Y; Ogura, H; Shinohara, K; Suzuki, Y1
Limmroth, V; Meissner, A1
Derfuss, T; Hawker, K; Meng, X; Nicholas, J; Ontaneda, D1
Barcella, V; Buoro, S; Conti, MZ; Dominoni, P; Frigeni, B; La Gioia, S; Mecca, T; Rottoli, M; Seghezzi, M; Vedovello, M; Vidali, M1
du Pasquier, R; Durand-Dubief, F; Marignier, R; Vukusic, S1
Costa, BK; Sato, DK1
Bhatia, R; Foucher, Y; Laplaud, DA1
Foucher, Y; Lanzillo, R; Laplaud, DA; Moccia, M1
Flood, E; Katic, B; Nafees, B; Rasouliyan, L; Sasané, R; Wicks, P1
Hartikainen, JE; Hartikainen, P; Laitinen, TM; Laitinen, TP; Simula, S2
Bianco, A; De Fino, C; Lucchini, M; Mirabella, M; Nociti, V; Patanella, AK; Rossini, PM; Savio, FL1
Goldman, MD; Jones, DE; Ward, MD1
Ando, K; Hashimoto, R; Kato, H; Ogawa, T; Otsuka, M; Tagawa, A; Tanabe, H; Tetsuka, S1
Bernard, JT; Grebenciucova, E; Reder, AT1
Merschhemke, M; Putzki, N; Tomic, D1
Andrade, C1
Graves, JS; Hatcher, SE; Waubant, E1
Brescia Morra, V; De Rosa, A; Matarazzo, M; Pane, C; Saccà, F1
Andreetta, F; Antozzi, C; Baggi, F; Bernasconi, P; Confalonieri, P; Consonni, A; Cordiglieri, C; Faggiani, E; Frangiamore, R; Kapetis, D; Mantegazza, R1
Arcaro, M; Calvi, A; Cioffi, SM; De Riz, M; Fenoglio, C; Galimberti, D; Oldoni, E; Pietroboni, AM; Scarpini, E; Serpente, M1
Chan, A; Edwards, MR; Fox, RJ; Levison, D; Lewin, JB; Marantz, JL; Xiao, J; Zhang, A1
Adachi, T; Fujii, C; Hashi, Y; Kondo, T; Matsumoto, S; Mizuno, T; Nakagawa, M; Ochi, H; Okada, Y; Shin-Ya, M; Takahashi, R1
Brescia Morra, V; Brogi, D; Comi, G; Guidi, L; Laroni, A; Lugaresi, A; Mancardi, GL; Pozzilli, C; Raimondi, D; Turrini, R; Uccelli, A1
Cifuentes-Canorea, P; Nieves-Moreno, M; Sáenz-Francés, F; Santos-Bueso, E1
Kadlecová, P; Kodým, R; Počíková, Z; Tichá, V1
Arru, G; Caocci, M; Dolei, A; Ibba, G; Leoni, S; Piu, C; Sechi, G; Serra, C; Uleri, E1
Belliston, S; Hammond, N; Lynch, S; Newell, K; Sundararajan, J1
Lasek-Bal, A; Puz, P1
Barnett, MH; Beadnall, HN; Gill, AJ; Riminton, S1
Al Hail, H; Bhagat, A; Canibano, B; Deleu, D; El Khider, H; Hanssens, Y; Ibrahim, F; Melikyan, G; Mesraoua, B; Mhjob, N1
Borgel, F; Bourdeix, I; Bungener, C; Chouette, I; Heinzlef, O; Meite, M; Moreau, T; Rerat, K; Suchet, L1
Koch-Henriksen, N; Magyari, M; Oturai, AB; Sellebjerg, F; Sørensen, PS; Voldsgaard, A1
Dive-Pouletty, C; Freedman, MS; Hass, S; Leist, TP; Miller, AE; Montalban, X; Thangavelu, K1
Bermel, RA; Cohen, JA; Cohn, S; Fox, RJ; Hara-Cleaver, C; Hersh, CM; Love, TE; Ontaneda, D1
Brescia Morra, V; Carotenuto, A; De Rosa, A; Lanzillo, R; Massarelli, M; Moccia, M; Russo, CV; Saccà, F1
Adlard, N; Kusel, J; Maruszczak, MJ; Montgomery, SM; Nicholas, R; Slater, D1
D'Onghia, M; Di Lecce, V; Direnzo, V; Iaffaldano, P; Manni, A; Paolicelli, D; Specchia, G; Tortorella, C; Trojano, M; Zoccolella, S1
Bargiela, D; Bianchi, MT; Chibnik, LB; De Jager, PL; Healy, BC; Westover, MB; Xia, Z1
Albert, C; Baier-Ebert, M; Dechend, R; Gerbershagen, K; Haas, J; Haverkamp, W; Hoffmann, O; Hoyer, S; Klotz, L; Lang, M; Lassek, C; Limmroth, V; Richter, S; Schieb, H; Schmidt, S; Schuh, K; Wagner, B; Wendt, G; Ziemssen, T1
Auberson, LZ; Hao, Q; Itoyama, Y; Kikuchi, S; Kira, JI; Kurosawa, T; Nagato, K; Saida, T; Tsumiyama, I; Ueda, K1
Tyor, WR; Vargas, DL1
Hartikainen, JEK; Hartikainen, P; Laitinen, TM; Laitinen, TP; Simula, S1
Alroughani, R; Ampapa, R; Barnett, M; Bergamaschi, R; Boz, C; Brown, JWL; Butzkueven, H; Coles, A; Cristiano, E; Csepany, T; Duquette, P; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Hutchinson, M; Izquierdo, G; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Lugaresi, A; McCombe, P; McGuigan, C; Olascoaga, J; Pearson, O; Prat, A; Pucci, E; Ramo, C; Rice, CM; Robertson, N; Rozsa, C; Sanchez-Menoyo, JL; Scolding, N; Simo, M; Slee, M; Sola, P; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Van Pesch, V; Verheul, F; Vucic, S; Wilkins, A; Willis, M; Ziemssen, T1
Bertrand, A; Boudot de la Motte, M; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Reach, P1
Candrian, U; Comi, G; Disanto, G; Ghezzi, A; Gobbi, C; Martinelli, V; Merlini, A; Messina, MJ; Moiola, L; Panicari, L; Patti, F; Perrone, P; Pravatà, E; Rodegher, M; Romeo, MAL; Stefanin, C; Zecca, C1
Adlard, N; Allen, F; Bending, M; Firth, Z; Huisman, E; Jarrett, J; Papadimitropoulou, K1
Benedetti, MD; Invernizzi, P; Monaco, S; Poli, S1
Bester, M; Gerloff, C; Heesen, C; Leypoldt, F; Moeller, F; Münchau, A1
Antel, J; Aradhye, S; Comi, G; Kappos, L; Karlsson, G; Montalban, X; O'Connor, P; Pohlmann, H; Radue, EW1
Agoropoulou, C; Burtin, P; Calabresi, P; Hohlfeld, R; Kappos, L; Leyk, M; O'Connor, P; Polman, C; Radue, EW; Selmaj, K; Zhang-Auberson, L1
Aradhye, S; Barkhof, F; Capra, R; Cohen, JA; Comi, G; de Vera, A; Gallo, P; Hartung, HP; Izquierdo, G; Jin, J; Kappos, L; Khatri, BO; Montalban, X; Pelletier, J; Stites, T; Tiel-Wilck, K; Wu, S1
Carroll, WM1
Castilló, J; Horga, A; Montalban, X1
Havla, J; Hohlfeld, R; Kümpfel, T2
Mann, H1
Marriott, JJ; O'Connor, PW1
Vasiliou, S1
Hosch, W; Korporal, M; Max, R; Schwarz, A; Wildemann, B1
Hartung, HP; Kieseier, BC; Stüve, O; Warnke, C; Wiendl, H1
Rabasseda, X1
Aradhye, S; Baumruker, T; Billich, A; Brinkmann, V; Burtin, P; Francis, G; Heining, P; Schmouder, R1
Borell, H; Jin, Y; Patten, CJ; Zimmerlin, A; Zollinger, M1
Choi, JW; Chun, J; Lee, CW1
Jeffery, DR; Markowitz, CE; Reder, AT; Tobias, K; Weinstock-Guttman, B1
Weinstock-Guttman, B; Yeh, EA1
Bassetti, M; Ginocchio, F; Mancardi, GL; Uccelli, A1
Berthele, A; Buck, D; Cepok, S; Hemmer, B; Hohlfeld, R; Korn, T; Kowarik, MC; Kümpfel, T; Pellkofer, HL1
Barkhof, F; Cohen, JA; Comi, G; Francis, G; Hartung, HP; Holdbrook, F; Kappos, L; Khatri, B; Montalban, X; Pelletier, J; Stites, T; Wu, S; Zhang-Auberson, L1
Antel, JP; Bar-Or, A; Blain, M; Durafourt, BA; Evans, BL; Johnson, TA; Lapierre, Y1
Ross, AP; Singer, B; Tobias, K1
Csépány, T1
Comi, G; de Vera, A; Eckert, B; Gold, S; Kappos, L; Montalban, X; O'Connor, P1
Baker, D; Giovannoni, G; Jackson, SJ1
Hohlfeld, R1
Scott, LJ1
Cohen, D1
Constantinescu, CS; Gran, B; Sanvito, L1
Huggins, A; Sergott, RC1
Killestein, J; Polman, CH; Rudick, RA1
Del Santo, F; Fadda, V; Maratea, D; Messori, A; Trippoli, S1
Sørensen, PS1
Campbell, C; Cryan, J; Deeks, N; Demont, E; Dowell, S; Garden, H; Gaskin, P; Gray, JR; Haynes, A; Leavens, K; Morse, M; Patel, A; Taylor, S; Willis, R; Witherington, J1
Bryan, JS; Turaka, K1
Buja, LM; Haden-Pinneri, K; Lindsey, JW; Memon, NB1
Gerdes, LA; Havla, JB; Hohlfeld, R; Kümpfel, T; Meinl, I; Pellkofer, HL1
Hao, Q; Itoyama, Y; Kikuchi, S; Kira, J; Kurosawa, T; Nagato, K; Saida, T; Tang, D; Zhang-Auberson, L1
Bhatti, MT; Jain, N1
Albrecht, H; Berthele, A; Castrop, F; Haslinger, B; Hemmer, B; Kowarik, MC; Krause, M; Zimmer, C1
Eckert, BJ; Roskell, NS; Rycroft, CE; Tyas, DA; Zimovetz, EA1
Rudick, RA1
Agoropoulou, C; Devonshire, V; Francis, G; Häring, DA; Havrdova, E; Kappos, L; O'Connor, P; Radue, EW; Zhang-Auberson, L1
Baxter, DC; Coleman, CI; Lee, S; Limone, B; Roberts, MS1
Jakab, G1
Frequin, ST; Groot, MT; Heisen, M; Treur, MJ; van der Hel, WS; Verheggen, BG1
Agashivala, N; Kim, E1
Cervera, C1
Amato, MP; Giannini, M; Hakiki, B; Pastò, L; Portaccio, E; Razzolini, L1
Berger, T; Fabjan, TH; Fazekas, F; Havrdová, E; Jakab, G; Jazbec, SS; Komoly, S; Kraus, J; Kurča, E; Kyriakides, T; Ledinek, AH; Lisý, L; Milanov, I; Panayiotou, P; Taláb, R; Traykov, L; Turčáni, P; Vass, K; Vella, N1
Chaunu, MP; Daelman, L; Maarouf, A; Maitrot, A; Papeix, C; Tourbah, A1
Bermel, RA; Cohen, JA; Hara-Cleaver, C; Ontaneda, D; Rudick, RA1
Calabrese, M; Gallo, P; Perini, P; Rinaldi, F; Seppi, D1
Abate, L; Brogi, D; Laroni, A; Mancardi, G; Milesi, V; Uccelli, A1
Bergvall, N; Fredrikson, S; Henriksson, F; Tambour, M1
Eienbröker, C; Gold, R; Havla, J; Hellwig, K; Hohlfeld, R; Kleiter, I; Krumbholz, M; Kümpfel, T; Meinl, I; Seitz, F; Tackenberg, B1
Park, K; Tanaka, K; Tanaka, M1
Berenguer-Ruiz, L; Feliu-Rey, E; Martín-Medina, P; Pérez-Carmona, N; Polache-Vengud, J; Sanchez-Perez, R; Sempere, AP1
Massberg, S; von Andrian, UH1
Antel, J; Comi, G; Haas, T; Kappos, L; Karlsson, G; Korn, AA; Montalban, X; O'Connor, P; Polman, CH; Radue, EW1
Horga, A; Montalban, X1

Reviews

75 review(s) available for fingolimod hydrochloride and Acute Relapsing Multiple Sclerosis

ArticleYear
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis.
    Multiple sclerosis and related disorders, 2022, Volume: 59

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Incidence; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasms

2022
BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2022, Volume: 75, Issue:3

    Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Skin Neoplasms

2022
Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:9

    Topics: Adult; Alemtuzumab; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Network Meta-Analysis

2022
Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
    Acta neurologica Scandinavica, 2022, Volume: 146, Issue:5

    Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Network Meta-Analysis; Off-Label Use; Rituximab

2022
Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review.
    Multiple sclerosis and related disorders, 2022, Volume: 68

    Topics: Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.
    Autoimmunity reviews, 2022, Volume: 21, Issue:12

    Topics: Anemia, Hemolytic, Autoimmune; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
    Neurology(R) neuroimmunology & neuroinflammation, 2022, Volume: 9, Issue:6

    Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
    Expert opinion on drug metabolism & toxicology, 2022, Volume: 18, Issue:10

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors

2022
Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
    Multiple sclerosis and related disorders, 2023, Volume: 73

    Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Gastrointestinal Microbiome; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2023
The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:4

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Recurrence

2020
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Neurology, 2020, 06-02, Volume: 94, Issue:22

    Topics: Cognition; Cognitive Dysfunction; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Randomized Controlled Trials as Topic

2020
[Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2020, Volume: 120, Issue:8

    Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2020
Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?
    Expert review of neurotherapeutics, 2021, Volume: 21, Issue:1

    Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic

2021
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.
    Multiple sclerosis and related disorders, 2021, Volume: 51

    Topics: Consensus; COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; RNA, Viral; SARS-CoV-2; Saudi Arabia

2021
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.
    Autoimmunity reviews, 2017, Volume: 16, Issue:6

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome

2017
Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines

2017
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:15

    Topics: Administration, Oral; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Risk Assessment; Treatment Outcome

2017
Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Multiple sclerosis and related disorders, 2017, Volume: 17

    Topics: Alemtuzumab; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Precision Medicine; Risk Assessment; Risk Factors; Treatment Outcome

2017
Multiple sclerosis, a treatable disease .
    Clinical medicine (London, England), 2017, Volume: 17, Issue:6

    Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines

2017
Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
    Journal of the neurological sciences, 2018, 05-15, Volume: 388

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Observational Studies as Topic

2018
Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatmen
    Current medical research and opinion, 2019, Volume: 35, Issue:8

    Topics: Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Tablets; Treatment Outcome

2019
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Journal of neurology, 2020, Volume: 267, Issue:12

    Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis

2020
[Update on current care guidelines: multiple sclerosis].
    Duodecim; laaketieteellinen aikakauskirja, 2013, Volume: 129, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Practice Guidelines as Topic; Propylene Glycols; Sphingosine

2013
Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012).
    Expert opinion on therapeutic patents, 2013, Volume: 23, Issue:7

    Topics: Animals; Bradycardia; Cognition Disorders; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Patents as Topic; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine

2013
Fingolimod for the treatment of relapsing multiple sclerosis.
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:6

    Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2013
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Current medical research and opinion, 2014, Volume: 30, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Randomized Controlled Trials as Topic; Recurrence; Sphingosine; Toluidines

2014
Management of fingolimod in clinical practice.
    Clinical neurology and neurosurgery, 2013, Volume: 115 Suppl 1

    Topics: Administration, Oral; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine

2013
An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    The American journal of managed care, 2013, Volume: 19, Issue:17 Suppl

    Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Crotonates; Daclizumab; Drug Approval; Female; Fingolimod Hydrochloride; Forecasting; Humans; Hydroxybutyrates; Immunoglobulin G; Injections, Intramuscular; Injections, Subcutaneous; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Patient Safety; Prognosis; Propylene Glycols; Severity of Illness Index; Sphingosine; Toluidines; Treatment Outcome

2013
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4

    Topics: Administration, Oral; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Treatment Outcome

2014
New management algorithms in multiple sclerosis.
    Current opinion in neurology, 2014, Volume: 27, Issue:3

    Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Clinical Protocols; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines

2014
Vagomimetic effects of fingolimod: physiology and clinical implications.
    CNS neuroscience & therapeutics, 2014, Volume: 20, Issue:6

    Topics: Animals; Atrioventricular Block; Bradycardia; Electrocardiography; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine

2014
Central effects of fingolimod.
    Revista de neurologia, 2014, Aug-01, Volume: 59, Issue:3

    Topics: Animals; Blood-Brain Barrier; Chemotaxis, Leukocyte; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunologic Memory; Mice; Mice, Knockout; Mice, Neurologic Mutants; Multicenter Studies as Topic; Multiple Sclerosis, Relapsing-Remitting; Neurogenesis; Neuroglia; Neuroprotective Agents; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets

2014
Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
    Drugs, 2014, Volume: 74, Issue:12

    Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2014
Update on disease-modifying treatments for multiple sclerosis.
    Clinical therapeutics, 2014, Dec-01, Volume: 36, Issue:12

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Quality of Life; Rituximab; Toluidines; Treatment Outcome

2014
Update on multiple sclerosis treatments.
    Swiss medical weekly, 2014, Volume: 144

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Sphingosine; Toluidines

2014
Current management of relapsing-remitting multiple sclerosis.
    Internal medicine journal, 2014, Volume: 44, Issue:10

    Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Risk Assessment; Sphingosine; Toluidines

2014
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Jan-01, Volume: 72, Issue:1

    Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Approval; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Sphingosine; Toluidines; United States; United States Food and Drug Administration

2015
[Oral treatments in multiple sclerosis].
    Medicina clinica, 2014, Volume: 143 Suppl 3

    Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines

2014
Oral agents in multiple sclerosis.
    Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2015, Volume: 14, Issue:1

    Topics: Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines

2015
Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin America.
    Advances in therapy, 2015, Volume: 32, Issue:7

    Topics: Fingolimod Hydrochloride; Health Services Accessibility; Humans; Immunosuppressive Agents; Latin America; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Socioeconomic Factors

2015
Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.
    Expert review of neurotherapeutics, 2016, Volume: 16, Issue:1

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols

2016
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016, Volume: 13, Issue:1

    Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines

2016
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
    CNS drugs, 2016, Volume: 30, Issue:2

    Topics: Animals; Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath

2016
[Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2015, Volume: 17, Issue:4

    Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines

2015
Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).
    Expert opinion on therapeutic patents, 2016, Volume: 26, Issue:4

    Topics: Animals; Autoimmune Diseases; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Patents as Topic; Receptors, Lysosphingolipid; Sphingosine

2016
Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
    Current opinion in neurology, 2016, Volume: 29, Issue:3

    Topics: Alemtuzumab; Fingolimod Hydrochloride; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2016
Fingolimod for relapsing-remitting multiple sclerosis.
    The Cochrane database of systematic reviews, 2016, Apr-19, Volume: 4

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Time Factors

2016
Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Multiple sclerosis and related disorders, 2016, Volume: 8

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting

2016
Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.
    Multiple sclerosis and related disorders, 2016, Volume: 9

    Topics: Cryptococcosis; Female; Fingolimod Hydrochloride; Humans; Immunosenescence; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocyte Subsets

2016
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Current medical research and opinion, 2017, Volume: 33, Issue:2

    Topics: Administration, Oral; Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome

2017
Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
    Current medical research and opinion, 2017, Volume: 33, Issue:3

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Interferons; Multiple Sclerosis, Relapsing-Remitting; Qatar

2017
Update on disease-modifying therapies for multiple sclerosis.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:5

    Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Infusions, Intravenous; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Polyomavirus Infections; Recurrence; Toluidines; Treatment Outcome; Tumor Virus Infections; United States; United States Food and Drug Administration

2017
Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    BMJ open, 2017, 03-10, Volume: 7, Issue:3

    Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Severity of Illness Index

2017
Azathioprine in multiple sclerosis.
    Mini reviews in medicinal chemistry, 2008, Volume: 8, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Chemistry, Pharmaceutical; Cyclophosphamide; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Methotrexate; Methyltransferases; Mitoxantrone; Models, Chemical; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine

2008
Fingolimod for relapsing multiple sclerosis: an update.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:7

    Topics: Administration, Oral; Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Sphingosine

2010
Emerging therapies in relapsing-remitting multiple sclerosis.
    Reviews on recent clinical trials, 2010, Volume: 5, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome

2010
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:5

    Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Interactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ketoconazole; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine

2010
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Drug design, development and therapy, 2010, Jul-21, Volume: 4

    Topics: Administration, Oral; Animals; Cladribine; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2010
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:11

    Topics: Administration, Oral; Animals; Drug Discovery; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Research; Sphingosine

2010
Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Archives of pharmacal research, 2010, Volume: 33, Issue:10

    Topics: Animals; Drugs, Investigational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Neuroglia; Phosphorylation; Prodrugs; Propylene Glycols; Protein Isoforms; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine

2010
Fingolimod for the treatment of relapsing multiple sclerosis.
    Expert review of neurotherapeutics, 2011, Volume: 11, Issue:2

    Topics: Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Lymphocytes; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine

2011
Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Advances in therapy, 2011, Volume: 28, Issue:4

    Topics: Activities of Daily Living; Administration, Oral; Bradycardia; Central Nervous System; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Macular Edema; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroimmunomodulation; Neurologic Examination; Propylene Glycols; Receptors, Lysosphingolipid; Recurrence; Sphingosine; Treatment Outcome; Young Adult

2011
Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    International journal of clinical practice, 2011, Volume: 65, Issue:8

    Topics: Administration, Oral; Adult; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Risk Factors; Secondary Prevention; Sphingosine; Treatment Outcome; Young Adult

2011
[Current treatment of multiple sclerosis].
    Lege artis medicinae : uj magyar orvosi hirmondo, 2011, Volume: 21, Issue:2

    Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome

2011
Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    CNS drugs, 2011, Volume: 25, Issue:8

    Topics: Administration, Oral; Adult; Animals; Drug Delivery Systems; Drug Interactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine

2011
Novel therapeutic approaches to autoimmune demyelinating disorders.
    Current pharmaceutical design, 2011, Volume: 17, Issue:29

    Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2011
Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Current opinion in ophthalmology, 2011, Volume: 22, Issue:6

    Topics: Administration, Oral; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome

2011
Oral treatment for multiple sclerosis.
    The Lancet. Neurology, 2011, Volume: 10, Issue:11

    Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines

2011
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Sphingosine

2012
Fingolimod-associated macular edema: incidence, detection, and management.
    Neurology, 2012, Feb-28, Volume: 78, Issue:9

    Topics: Fingolimod Hydrochloride; Humans; Macular Edema; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2012
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Current medical research and opinion, 2012, Volume: 28, Issue:5

    Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Peptides; Poisson Distribution; Propylene Glycols; Recurrence; Sphingosine; Time Factors

2012
[2012: Update on diagnosis and treatment of multiple sclerosis].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:17

    Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Immunosuppressive Agents; Infusions, Intravenous; Interferon-beta; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Plasmapheresis; Propylene Glycols; Pulse Therapy, Drug; Sphingosine; Spinal Cord

2012
[Infections and fingolimod].
    Revista de neurologia, 2012, Aug-16, Volume: 55, Issue:4

    Topics: Community-Acquired Infections; Contraindications; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunocompromised Host; Immunologic Memory; Immunologic Surveillance; Immunosuppressive Agents; Kidney Transplantation; Leukoencephalopathy, Progressive Multifocal; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Opportunistic Infections; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Vaccination

2012
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:15-16

    Topics: Administration, Oral; Algorithms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunologic Memory; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Lymphocyte Count; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes; Treatment Outcome

2012
FTY720 (fingolimod) for relapsing multiple sclerosis.
    Expert review of neurotherapeutics, 2008, Volume: 8, Issue:5

    Topics: Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine; Treatment Outcome

2008

Trials

68 trial(s) available for fingolimod hydrochloride and Acute Relapsing Multiple Sclerosis

ArticleYear
Baseline retinal nerve fiber layer thickness as a predictor of multiple sclerosis progression: New insights from the FREEDOMS II study.
    European journal of neurology, 2023, Volume: 30, Issue:2

    Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers; Retina; Tomography, Optical Coherence

2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    Journal of neurology, neurosurgery, and psychiatry, 2023, Volume: 94, Issue:12

    Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pregnancy; Recurrence

2023
Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Journal of neuroimmunology, 2019, 12-15, Volume: 337

    Topics: Adult; CD4-Positive T-Lymphocytes; Cytokines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies

2019
Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Multiple sclerosis and related disorders, 2019, Volume: 36

    Topics: Adult; Early Medical Intervention; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon beta-1a; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Secondary Prevention; Severity of Illness Index

2019
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Journal of comparative effectiveness research, 2020, Volume: 9, Issue:4

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indans; Liver; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Oxadiazoles

2020
Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Journal of neurology, neurosurgery, and psychiatry, 2020, Volume: 91, Issue:5

    Topics: Adult; Atrophy; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Immunologic Factors; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroimaging; Prospective Studies; White Matter

2020
Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design).
    Clinical pharmacology in drug development, 2020, Volume: 9, Issue:5

    Topics: Administration, Oral; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Cytochrome P450 Family 4; Drug Compounding; Fasting; Female; Fingolimod Hydrochloride; Healthy Volunteers; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; New Zealand; Sphingosine 1 Phosphate Receptor Modulators; Therapeutic Equivalency

2020
Evaluation of the effect of fingolimod (FTY720) on macular perfusion by swept-source optical coherence tomography angiography in patients with multiple sclerosis.
    Cutaneous and ocular toxicology, 2020, Volume: 39, Issue:3

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macula Lutea; Male; Microcirculation; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Regional Blood Flow; Sphingosine 1 Phosphate Receptor Modulators; Tomography, Optical Coherence; Young Adult

2020
Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes
    Multiple sclerosis and related disorders, 2020, Volume: 45

    Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Personal Satisfaction; Prospective Studies; Treatment Outcome

2020
Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS.
    Multiple sclerosis and related disorders, 2020, Volume: 46

    Topics: Fingolimod Hydrochloride; Freedom; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2020
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
    BMJ open, 2020, 10-20, Volume: 10, Issue:10

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Treatment Outcome

2020
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:14

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
    Journal of neurology, 2017, Volume: 264, Issue:11

    Topics: Adolescent; Adult; Blood Pressure; Female; Fingolimod Hydrochloride; Follow-Up Studies; Heart Diseases; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Time Factors; Valsalva Maneuver; Young Adult

2017
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    Journal of neurology, 2017, Volume: 264, Issue:12

    Topics: Adolescent; Adult; Cognition Disorders; Depression; Disability Evaluation; Electrocardiography; Executive Function; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon beta-1b; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Pilot Projects; Statistics, Nonparametric; Treatment Outcome; Young Adult

2017
Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial.
    Clinical neurology and neurosurgery, 2017, Volume: 163

    Topics: Adolescent; Adult; Anti-Inflammatory Agents; Disability Evaluation; Double-Blind Method; Female; Fingolimod Hydrochloride; Fish Oils; Humans; Interleukin-6; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2017
The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.
    Oxidative medicine and cellular longevity, 2017, Volume: 2017

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunomodulation; Immunosuppressive Agents; Lipid Peroxides; Lipofuscin; Male; Malondialdehyde; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Oxidative Stress

2017
Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
    Journal of neurology, 2018, Volume: 265, Issue:2

    Topics: Adult; Dietary Supplements; Disability Evaluation; Disease Progression; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; International Cooperation; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Regression Analysis; Time Factors; Vitamin D

2018
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology, 2018, 04-10, Volume: 90, Issue:15

    Topics: Aged; Atrophy; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Thalamus; Treatment Outcome; White Matter

2018
Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.
    Neurosciences (Riyadh, Saudi Arabia), 2018, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Iran; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2018
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Neurology, 2018, 07-10, Volume: 91, Issue:2

    Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Product Surveillance, Postmarketing; Propensity Score; Retrospective Studies; Treatment Outcome; Young Adult

2018
The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    Journal of neurology, 2018, Volume: 265, Issue:9

    Topics: Adolescent; Adult; Atrophy; Disease Progression; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Single-Blind Method; Young Adult

2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    The New England journal of medicine, 2018, 09-13, Volume: 379, Issue:11

    Topics: Administration, Oral; Adolescent; Brain; Child; Female; Fingolimod Hydrochloride; Headache; Humans; Immunologic Factors; Infections; Injections, Intramuscular; Interferon-beta; Leukopenia; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Secondary Prevention

2018
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Neurology, 2019, 03-05, Volume: 92, Issue:10

    Topics: Adult; Biomarkers; Brain; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neurofilament Proteins; Prognosis

2019
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
    Journal of neurology, 2013, Volume: 260, Issue:8

    Topics: Adult; Aging; Analysis of Variance; Brain; Data Interpretation, Statistical; Female; Fingolimod Hydrochloride; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome

2013
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
    Journal of medical economics, 2013, Volume: 16, Issue:7

    Topics: Canada; Drug Tolerance; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient-Centered Care; Propylene Glycols; Quality of Life; Sphingosine; Standard of Care; Treatment Outcome; United States

2013
Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2013, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macula Lutea; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers; North America; Propylene Glycols; Retina; Retrospective Studies; Sphingosine; Tomography, Optical Coherence; Young Adult

2013
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
    Journal of neurology, 2014, Volume: 261, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Bradycardia; Disability Evaluation; Electrocardiography; Endpoint Determination; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Diseases; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Safety; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult

2014
Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:7

    Topics: Administration, Oral; Disability Evaluation; Disease Progression; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Time Factors; Treatment Outcome

2014
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
    BMC neurology, 2014, Jan-29, Volume: 14

    Topics: Adolescent; Adult; Asian People; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult

2014
Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
    Journal of neuroimmunology, 2014, Mar-15, Volume: 268, Issue:1-2

    Topics: Cell Separation; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes, Regulatory; Th17 Cells

2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    The Lancet. Neurology, 2014, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Secondary Prevention; Sphingosine; Treatment Outcome; Young Adult

2014
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:13

    Topics: Adult; Brain; Double-Blind Method; Drug Combinations; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2014
Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Advances in therapy, 2014, Volume: 31, Issue:10

    Topics: Adult; Double-Blind Method; Drug Monitoring; Female; Fingolimod Hydrochloride; Hispanic or Latino; Humans; Immunosuppressive Agents; Interferon beta-1a; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Secondary Prevention; Treatment Outcome

2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    BMC neurology, 2014, Nov-26, Volume: 14

    Topics: Adult; Aged; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Injections, Intramuscular; Interferon beta-1a; Interferon beta-1b; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2014
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Contemporary clinical trials, 2015, Volume: 41

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Double-Blind Method; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Interferon beta-1a; Linear Models; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Time Factors; Treatment Outcome; Young Adult

2015
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Annals of neurology, 2015, Volume: 77, Issue:3

    Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Registries; Severity of Illness Index; Sphingosine; Treatment Outcome

2015
Fingolimod effect on brain volume loss independently contributes to its effect on disability.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:7

    Topics: Adult; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting

2015
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Neurology, 2015, Apr-14, Volume: 84, Issue:15

    Topics: Adolescent; Adult; Brain; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Single-Blind Method; Sphingosine; Treatment Outcome; Young Adult

2015
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
    Neurology, 2015, Apr-21, Volume: 84, Issue:16

    Topics: Adult; Axons; Biomarkers; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intermediate Filaments; Male; Multiple Sclerosis, Relapsing-Remitting; Neurofibrils; Placebos; Propylene Glycols; Sphingosine; Treatment Outcome

2015
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
    Journal of neurology, neurosurgery, and psychiatry, 2016, Volume: 87, Issue:5

    Topics: Adult; Disability Evaluation; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Recurrence; Treatment Outcome; Young Adult

2016
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
    Current medical research and opinion, 2015, Volume: 31, Issue:9

    Topics: Adult; Disease Progression; Drug Monitoring; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Acuity; Secondary Prevention; Treatment Outcome

2015
Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Advances in therapy, 2015, Volume: 32, Issue:7

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Research Design; United States

2015
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Multiple sclerosis and related disorders, 2014, Volume: 3, Issue:5

    Topics: Administration, Oral; Canada; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; United States

2014
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Multiple sclerosis and related disorders, 2014, Volume: 3, Issue:5

    Topics: Administration, Oral; Canada; Dose-Response Relationship, Drug; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; United States

2014
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
    Multiple sclerosis and related disorders, 2014, Volume: 3, Issue:5

    Topics: Administration, Oral; Arrhythmias, Cardiac; Canada; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; United States

2014
Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
    Journal of neurology, 2015, Volume: 262, Issue:12

    Topics: Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care

2015
The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
    Journal of neurology, 2016, Volume: 263, Issue:2

    Topics: Adult; Brain; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting

2016
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
    Journal of neurology, 2016, Volume: 263, Issue:2

    Topics: Adult; Brain; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
    Annals of neurology, 2016, Volume: 79, Issue:6

    Topics: Adult; Antibodies; Female; Fingolimod Hydrochloride; Humans; JC Virus; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Registries; Rituximab; Treatment Outcome; Young Adult

2016
The effectiveness of fingolimod in a Portuguese real-world population.
    Multiple sclerosis and related disorders, 2016, Volume: 6

    Topics: Adolescent; Adult; Aged; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Portugal; Retreatment; Retrospective Studies; Treatment Outcome; Young Adult

2016
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
    Journal of the neurological sciences, 2016, Jun-15, Volume: 365

    Topics: Adolescent; Adult; Aged; Depressive Disorder; Disability Evaluation; Drug Administration Routes; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult

2016
Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    Multiple sclerosis and related disorders, 2016, Volume: 7

    Topics: Adolescent; Adult; Brain; Double-Blind Method; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Regression Analysis; Time Factors; Treatment Outcome; Young Adult

2016
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
    Multiple sclerosis and related disorders, 2016, Volume: 8

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Age Factors; Disability Evaluation; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; Young Adult

2016
Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
    BMC neurology, 2016, Aug-08, Volume: 16

    Topics: Disease Progression; Documentation; Drug Monitoring; Electronic Health Records; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Safety; Treatment Outcome

2016
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:1

    Topics: Adult; Female; Fingolimod Hydrochloride; Headache; Humans; Immunosuppressive Agents; Infections; Italy; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2017
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Multiple sclerosis and related disorders, 2016, Volume: 10

    Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Evidence-Based Medicine; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Numbers Needed To Treat; Recurrence; Severity of Illness Index; Toluidines; Treatment Outcome

2016
Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study.
    BMC neurology, 2017, Jan-28, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Young Adult

2017
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2010, Volume: 16, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome; Young Adult

2010
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    The New England journal of medicine, 2010, Feb-04, Volume: 362, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Liver Function Tests; Macular Edema; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult

2010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    The New England journal of medicine, 2010, Feb-04, Volume: 362, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Intention to Treat Analysis; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Statistics, Nonparametric; Young Adult

2010
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Neurology, 2011, Apr-05, Volume: 76, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes; Young Adult

2011
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    The Lancet. Neurology, 2011, Volume: 10, Issue:6

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult

2011
Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
    Journal of immunology (Baltimore, Md. : 1950), 2011, Jul-01, Volume: 187, Issue:1

    Topics: CD56 Antigen; Cells, Cultured; Chemotaxis, Leukocyte; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunophenotyping; Immunosuppressive Agents; Killer Cells, Natural; Lymphocyte Count; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2011
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2011, Volume: 17, Issue:11

    Topics: Administration, Oral; Adult; Canada; Chi-Square Distribution; Depression; Double-Blind Method; Europe; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Psychiatric Status Rating Scales; Quality of Life; Sphingosine; Surveys and Questionnaires; Time Factors; Treatment Outcome

2011
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:9

    Topics: Adolescent; Adult; Asian People; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Japan; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Odds Ratio; Propylene Glycols; Recurrence; Sphingosine; Time Factors; Treatment Outcome; Young Adult

2012
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    The Lancet. Neurology, 2012, Volume: 11, Issue:5

    Topics: Administration, Oral; Adult; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Proportional Hazards Models; Propylene Glycols; Secondary Prevention; Sex Factors; Sphingosine

2012
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Clinical therapeutics, 2012, Volume: 34, Issue:7

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome; Young Adult

2012
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adolescent; Adult; Brain; Brain Diseases; Double-Blind Method; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Respiratory Tract Infections; Sphingosine; Statistics, Nonparametric

2006

Other Studies

462 other study(ies) available for fingolimod hydrochloride and Acute Relapsing Multiple Sclerosis

ArticleYear
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:4

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Recurrence; Retrospective Studies

2021
Skin care advice to patients with multiple sclerosis on Fingolimod treatment at increased risk of skin malignancy-room for improvement?
    Irish journal of medical science, 2022, Volume: 191, Issue:4

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Skin Care; Skin Neoplasms

2022
Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:3

    Topics: Cohort Studies; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome

2022
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    CNS drugs, 2021, Volume: 35, Issue:11

    Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agents; Internationality; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Secondary Prevention

2021
A real-world study of alemtuzumab in a cohort of Italian patients.
    European journal of neurology, 2022, Volume: 29, Issue:1

    Topics: Adult; Alemtuzumab; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies

2022
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:4

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies

2021
Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:4

    Topics: Adolescent; Adult; Child; Fingolimod Hydrochloride; HLA-DRB1 Chains; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2022
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2022
Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2021, Volume: 56

    Topics: Biomarkers; Fingolimod Hydrochloride; Glial Fibrillary Acidic Protein; Humans; Intermediate Filaments; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neurofilament Proteins

2021
Factors associated with fingolimod rebound: A single center real-life experience.
    Multiple sclerosis and related disorders, 2021, Volume: 56

    Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies

2021
Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis.
    JAMA network open, 2021, 11-01, Volume: 4, Issue:11

    Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Rituximab

2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
    PharmacoEconomics, 2022, Volume: 40, Issue:3

    Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2022
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    Journal of neurology, 2022, Volume: 269, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2022
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    Journal of neurology, 2022, Volume: 269, Issue:6

    Topics: Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2022
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    Journal of neurology, 2022, Volume: 269, Issue:5

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2022
Acute Varicella-Zoster Virus meningitis in a multiple sclerosis patient treated with fingolimod.
    Revue neurologique, 2022, Volume: 178, Issue:4

    Topics: Fingolimod Hydrochloride; Herpesvirus 3, Human; Humans; Meningitis; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Neurology(R) neuroimmunology & neuroinflammation, 2022, Volume: 9, Issue:2

    Topics: Adult; Age Factors; Case-Control Studies; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time Factors

2022
Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patients.
    Pharmacogenomics, 2022, Volume: 23, Issue:3

    Topics: Adult; CX3C Chemokine Receptor 1; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Oligonucleotide Array Sequence Analysis; Receptors, CCR7; Sequence Analysis, RNA; T-Lymphocytes; Transcriptome

2022
Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia.
    Psychiatria Danubina, 2021, Volume: 33, Issue:Suppl 13

    Topics: Croatia; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Rebound activity after fingolimod cessation: A case - control study.
    Multiple sclerosis and related disorders, 2022, Volume: 57

    Topics: Case-Control Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Retrospective Studies

2022
Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Adult; Antigens, CD19; Antigens, CD20; B-Lymphocytes; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon-beta; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; T-Lymphocytes

2022
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022, Volume: 19, Issue:2

    Topics: Antigens, CD20; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2022
Multiple Sclerosis Relapses Following Cessation of Fingolimod.
    Clinical drug investigation, 2022, Volume: 42, Issue:4

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2022
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
    Current medical research and opinion, 2022, Volume: 38, Issue:7

    Topics: Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries; Tablets

2022
Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
    BMC neurology, 2022, Apr-15, Volume: 22, Issue:1

    Topics: Czech Republic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome

2022
The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.
    PloS one, 2022, Volume: 17, Issue:4

    Topics: Adult; Cross-Sectional Studies; Fingolimod Hydrochloride; Humans; Hungary; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2022
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Multiple sclerosis and related disorders, 2022, Volume: 62

    Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Rituximab

2022
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Multiple sclerosis and related disorders, 2022, Volume: 61

    Topics: Adult; Cladribine; Cohort Studies; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Tablets

2022
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2022, Volume: 63

    Topics: Adult; Cladribine; Cohort Studies; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Motor Disorders; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.
    Neurology(R) neuroimmunology & neuroinflammation, 2022, Volume: 9, Issue:4

    Topics: Adult; Antigens, CD20; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Sphingosine-1-Phosphate Receptors

2022
Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study.
    Multiple sclerosis and related disorders, 2022, Volume: 63

    Topics: Adult; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Male; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Rituximab; Young Adult

2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.
    BMC medical research methodology, 2022, 05-30, Volume: 22, Issue:1

    Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome

2022
Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    Journal of neurology, 2022, Volume: 269, Issue:10

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Severity of Illness Index

2022
Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2022, Volume: 39

    Topics: Child; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies

2022
Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    Journal of neuroimmunology, 2022, 09-15, Volume: 370

    Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gait; Mice; Mice, Inbred C57BL; Multiple Sclerosis, Relapsing-Remitting; Spinal Cord

2022
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:1

    Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2023
Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
    Multiple sclerosis and related disorders, 2022, Volume: 66

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Recurrence; Retrospective Studies

2022
[Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:7. Vyp. 2

    Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets

2022
Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2022, Volume: 32, Issue:6

    Topics: Fatigue; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
How to choose initial treatment in multiple sclerosis patients: a case-based approach.
    Arquivos de neuro-psiquiatria, 2022, Volume: 80, Issue:5 Suppl 1

    Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology, 2022, 10-25, Volume: 99, Issue:17

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies

2022
Treatment-refractory warts associated with fingolimod.
    Practical neurology, 2022, Volume: 22, Issue:6

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Warts

2022
Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.
    Multiple sclerosis and related disorders, 2022, Volume: 68

    Topics: Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Postpartum Period; Pregnancy; Recurrence

2022
The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
    Advances in therapy, 2022, Volume: 39, Issue:11

    Topics: Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Qualitative Research; Recurrence; Toluidines

2022
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    Journal of neurology, 2023, Volume: 270, Issue:1

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies

2023
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany.
    Multiple sclerosis and related disorders, 2022, Volume: 67

    Topics: Child; Cladribine; Cross-Sectional Studies; Drug Utilization; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy

2022
What are the trends in the treatment of multiple sclerosis in recent studies? - A bibliometric analysis with global productivity during 1980-2021.
    Multiple sclerosis and related disorders, 2022, Volume: 68

    Topics: Alemtuzumab; COVID-19; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Recurrence

2022
Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina.
    Arquivos de neuro-psiquiatria, 2022, Volume: 80, Issue:7

    Topics: Adult; Argentina; Biomarkers; Brain; Cognitive Dysfunction; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies

2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
    Journal of neurology, neurosurgery, and psychiatry, 2022, Volume: 93, Issue:12

    Topics: Cladribine; Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Withholding Treatment

2022
Modulation of salivary ICAM-1 and SIRT1 by disease modifying drugs in undepressed relapsing-remitting multiple sclerosis patients.
    Multiple sclerosis and related disorders, 2022, Volume: 68

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Sirtuin 1

2022
Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.
    The neuroradiology journal, 2023, Volume: 36, Issue:4

    Topics: Benchmarking; Brain; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; White Matter

2023
Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
    Neurology(R) neuroimmunology & neuroinflammation, 2023, Volume: 10, Issue:1

    Topics: Chemokine CXCL13; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2023
Using an animal model to predict the effective human dose for oral multiple sclerosis drugs.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Animals; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Rats

2023
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:2

    Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets

2023
Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:2

    Topics: Fingolimod Hydrochloride; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2023
Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman.
    BMC ophthalmology, 2022, Dec-05, Volume: 22, Issue:1

    Topics: Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Longitudinal Studies; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Oman; Retrospective Studies

2022
Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Neurology, 2023, 04-04, Volume: 100, Issue:14

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mpox (monkeypox); Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2023
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Neurology, 2023, 03-14, Volume: 100, Issue:11

    Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting

2023
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:6

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome

2023
Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
    Multiple sclerosis and related disorders, 2023, Volume: 70

    Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Smoking

2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.
    Multiple sclerosis and related disorders, 2023, Volume: 70

    Topics: Adult; Comparative Effectiveness Research; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome

2023
Comparative effectiveness in multiple sclerosis: A methodological comparison.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:3

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Treatment Outcome

2023
A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study.
    Revue neurologique, 2023, Volume: 179, Issue:6

    Topics: Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2023
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
    Journal of neurology, 2023, Volume: 270, Issue:6

    Topics: Austria; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome

2023
Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2023, Volume: 71

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome

2023
A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
    Advances in therapy, 2023, Volume: 40, Issue:5

    Topics: Adult; Female; Fingolimod Hydrochloride; Greece; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Recurrence; Treatment Outcome

2023
Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor.
    Journal of immunology research, 2023, Volume: 2023

    Topics: Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Humans; Immune System; Interferon-gamma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2023
The consequences of switching from Gilenya® to generics for fingolimod.
    Multiple sclerosis and related disorders, 2023, Volume: 74

    Topics: Adult; Drugs, Generic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome

2023
Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuromyelitis Optica

2023
Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
    Cardiology in the young, 2023, Volume: 33, Issue:11

    Topics: Adolescent; Atrioventricular Block; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Young Adult

2023
miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.
    Journal of neuroinflammation, 2023, May-30, Volume: 20, Issue:1

    Topics: Adolescent; Autoimmune Diseases; Biomarkers; Fingolimod Hydrochloride; Humans; MicroRNAs; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
    JAMA neurology, 2023, 07-01, Volume: 80, Issue:7

    Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasm Recurrence, Local; Recurrence

2023
Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
    European journal of neurology, 2023, Volume: 30, Issue:9

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2023
Current and future trends in multiple sclerosis management: Near East perspective.
    Multiple sclerosis and related disorders, 2023, Volume: 76

    Topics: COVID-19; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Lebanon; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2023
Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod.
    Multiple sclerosis and related disorders, 2023, Volume: 76

    Topics: Arrhythmias, Cardiac; Electrocardiography; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2023
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
    Multiple sclerosis and related disorders, 2023, Volume: 76

    Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets

2023
Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis.
    Multiple sclerosis and related disorders, 2023, Volume: 77

    Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
    JAMA neurology, 2023, 07-01, Volume: 80, Issue:7

    Topics: Adult; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2023
Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting.
    Multiple sclerosis and related disorders, 2023, Volume: 77

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Patient Reported Outcome Measures; Retrospective Studies

2023
Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
    Turkish journal of medical sciences, 2023, Volume: 53, Issue:3

    Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Universities

2023
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.
    Multiple sclerosis and related disorders, 2023, Volume: 79

    Topics: Adolescent; Child; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2023
A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation.
    Revue neurologique, 2023, Volume: 179, Issue:9

    Topics: Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies

2023
The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
    BMC research notes, 2023, Oct-16, Volume: 16, Issue:1

    Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon-gamma; Leukocytes, Mononuclear; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurodegenerative Diseases

2023
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria.
    Revista de neurologia, 2023, Nov-30, Volume: 77, Issue:s04

    Topics: Adult; Bulgaria; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life

2023
Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.
    BMC neurology, 2019, Aug-09, Volume: 19, Issue:1

    Topics: Adult; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting

2019
Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020, Volume: 17, Issue:1

    Topics: Adult; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Treatment Outcome

2020
Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.
    Neurology(R) neuroimmunology & neuroinflammation, 2019, Volume: 6, Issue:5

    Topics: Administration, Oral; Adult; Chemical and Drug Induced Liver Injury; Demyelinating Diseases; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult

2019
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2019, Volume: 36

    Topics: Adult; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Propensity Score; Retrospective Studies; Secondary Prevention; Severity of Illness Index; Toluidines

2019
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    Journal of the neurological sciences, 2019, Oct-15, Volume: 405

    Topics: Adolescent; Adult; Aged; Autonomic Agents; Drug Monitoring; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Young Adult

2019
Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    Journal of neuroimmunology, 2019, 12-15, Volume: 337

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Biomarkers; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interleukin-22; Interleukins; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Random Allocation; Young Adult

2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
    Journal of neurology, 2019, Volume: 266, Issue:12

    Topics: Adult; Disease Progression; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon beta-1a; Italy; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Registries; Retrospective Studies; Severity of Illness Index

2019
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
    JAMA neurology, 2020, 02-01, Volume: 77, Issue:2

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Infections; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Rituximab; Sweden

2020
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
    Journal of the neurological sciences, 2019, Dec-15, Volume: 407

    Topics: Adult; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome

2019
The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    PloS one, 2019, Volume: 14, Issue:10

    Topics: Adult; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Poland; Prognosis; Prospective Studies; Survival Rate

2019
Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.
    Revue neurologique, 2020, Volume: 176, Issue:4

    Topics: Adult; Demyelinating Diseases; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Rituximab

2020
Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    BMC neurology, 2019, Nov-15, Volume: 19, Issue:1

    Topics: Adult; Atrioventricular Block; Electroencephalography; Female; Fingolimod Hydrochloride; Heart Rate; Home Care Services, Hospital-Based; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Satisfaction; Retrospective Studies

2019
Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.
    Journal of neuroinflammation, 2019, Nov-16, Volume: 16, Issue:1

    Topics: Adult; B-Lymphocytes; Cell Differentiation; Cells, Cultured; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Lymphocyte Activation; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2019
Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod.
    Dermatology online journal, 2019, Sep-15, Volume: 25, Issue:9

    Topics: Biopsy; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; In Situ Hybridization; Lymphocytes; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; RNA, Viral; Skin; Skin Diseases, Viral; Sphingosine 1 Phosphate Receptor Modulators

2019
Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
    Journal of neuroimmunology, 2020, 02-15, Volume: 339

    Topics: Animals; Brain; Cuprizone; Female; Fingolimod Hydrochloride; Mice; Mice, Inbred C57BL; Multiple Sclerosis, Relapsing-Remitting; Neuroprotection; Random Allocation; Remyelination; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors

2020
Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
    Multiple sclerosis and related disorders, 2020, Volume: 38

    Topics: Atrioventricular Block; Cardiac Resynchronization Therapy Devices; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2020
Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
    Multiple sclerosis and related disorders, 2020, Volume: 38

    Topics: Adult; Alemtuzumab; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting

2020
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.
    Multiple sclerosis and related disorders, 2020, Volume: 38

    Topics: Adult; Alemtuzumab; Behavioral Symptoms; Brain Diseases; Brain Stem; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Mutism; Recurrence; White Matter; Young Adult

2020
Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination.
    International journal of molecular sciences, 2019, Nov-28, Volume: 20, Issue:23

    Topics: Adult; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Yellow Fever Vaccine

2019
Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
    Multiple sclerosis and related disorders, 2020, Volume: 38

    Topics: Adult; Antigens, Viral; CD8 Antigens; Female; Fingolimod Hydrochloride; Herpesvirus 3, Human; Humans; Immediate-Early Proteins; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Receptors, CCR7; T-Lymphocytes; Trans-Activators; Viral Envelope Proteins

2020
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Advances in therapy, 2020, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Cladribine; Costs and Cost Analysis; Drug Costs; Female; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2020
Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling.
    Multiple sclerosis and related disorders, 2020, Volume: 40

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Rituximab; T-Lymphocytes; Transcriptome

2020
Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
    Neurology(R) neuroimmunology & neuroinflammation, 2020, Volume: 7, Issue:2

    Topics: Adult; Dimethyl Fumarate; Europe; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Survival Analysis

2020
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Journal of medical economics, 2020, Volume: 23, Issue:5

    Topics: Adult; Age of Onset; Cladribine; Cost-Benefit Analysis; Disease Progression; Female; Fingolimod Hydrochloride; Health Expenditures; Health Resources; Humans; Immunosuppressive Agents; Male; Markov Chains; Middle Aged; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Portugal; Quality-Adjusted Life Years

2020
Severe fingolimod rebound syndrome after switching to cladribine treatment.
    Multiple sclerosis and related disorders, 2020, Volume: 40

    Topics: Adult; Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2020
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series.
    Multiple sclerosis and related disorders, 2020, Volume: 40

    Topics: Adult; Antibodies, Viral; Female; Fingolimod Hydrochloride; Follow-Up Studies; Herpes Zoster Vaccine; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies

2020
Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
    Value in health regional issues, 2020, Volume: 23

    Topics: Colombia; Cost of Illness; Cost-Benefit Analysis; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunologic Factors; Immunosuppressive Agents; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2020
Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adult; B-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Killer Cells, Natural; Lymphocyte Subsets; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes, Regulatory

2020
Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    BMC medical research methodology, 2020, 02-07, Volume: 20, Issue:1

    Topics: Algorithms; Bayes Theorem; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Models, Theoretical; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Precision Medicine; Prognosis; Recurrence; Treatment Adherence and Compliance

2020
A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
    Multiple sclerosis and related disorders, 2020, Volume: 40

    Topics: Adult; Brain; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting

2020
Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    PloS one, 2020, Volume: 15, Issue:3

    Topics: Administrative Claims, Healthcare; Adult; Aged; Brazil; Female; Fingolimod Hydrochloride; Hospitalization; Hospitals, Public; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2020
Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod.
    Multiple sclerosis and related disorders, 2020, Volume: 41

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Mycoses; Necrosis; Opportunistic Infections; Osteomyelitis

2020
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study.
    Neurology(R) neuroimmunology & neuroinflammation, 2020, Volume: 7, Issue:3

    Topics: Adult; Aged; Cross-Sectional Studies; Disease Progression; Female; Fingolimod Hydrochloride; Flow Cytometry; Germany; Humans; Immunologic Factors; Immunophenotyping; Immunotherapy; Italy; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Norway; Spain; Young Adult

2020
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
    European neurology, 2020, Volume: 83, Issue:1

    Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Spain

2020
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
    Multiple sclerosis and related disorders, 2020, Volume: 42

    Topics: Aged; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2020
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2021, 03-01, Volume: 41, Issue:1

    Topics: Adult; Central Serous Chorioretinopathy; Choroid; Coloring Agents; Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Immunosuppressive Agents; Indocyanine Green; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tomography, Optical Coherence; Visual Acuity

2021
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Adult; Aged; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Spain

2020
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Journal of neurology, 2020, Volume: 267, Issue:7

    Topics: Administration, Oral; Adult; Austria; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Registries; Severity of Illness Index; Toluidines

2020
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:10

    Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies

2020
Cryptococcal meningoencephalitis in an IgG
    BMC neurology, 2020, Apr-27, Volume: 20, Issue:1

    Topics: Cryptococcosis; Female; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunosuppressive Agents; Lymphopenia; Meningoencephalitis; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Opportunistic Infections

2020
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
    Revue neurologique, 2020, Volume: 176, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; SARS-CoV-2

2020
Real-world incidence of fingolimod-associated macular oedema.
    Multiple sclerosis and related disorders, 2020, Volume: 42

    Topics: Adult; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; London; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Tomography, Optical Coherence

2020
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
    Multiple sclerosis and related disorders, 2020, Volume: 42

    Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Deprescriptions; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Noninvasive Ventilation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed

2020
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
    Multiple sclerosis and related disorders, 2020, Volume: 42

    Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deprescriptions; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interleukin-6; L-Lactate Dehydrogenase; Lymphopenia; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index

2020
Comparison of brain atrophy in patients with multiple sclerosis treated with first- versus second-generation disease modifying therapy without clinical relapse.
    European journal of neurology, 2020, Volume: 27, Issue:10

    Topics: Atrophy; Brain; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2020
COVID-19 in MS: Initial observations from the Pacific Northwest.
    Neurology(R) neuroimmunology & neuroinflammation, 2020, 09-03, Volume: 7, Issue:5

    Topics: Adult; Aged; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunocompromised Host; Immunosuppressive Agents; Interferons; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Northwestern United States; Nursing Homes; Oregon; Pandemics; Pneumonia, Viral; Severity of Illness Index; Toluidines; Travel; Washington

2020
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Multiple sclerosis and related disorders, 2020, Volume: 43

    Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed

2020
Disability progression
    Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:3

    Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2021
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
    Multiple sclerosis and related disorders, 2020, Volume: 43

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chile; Coronavirus Infections; COVID-19; Decision Making; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Guideline Adherence; Guidelines as Topic; Health Behavior; Humans; Immunologic Factors; Interferons; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; Quarantine; SARS-CoV-2; World Health Organization; Young Adult

2020
Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Clinical neurology and neurosurgery, 2020, Volume: 195

    Topics: Adult; Drug Eruptions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pityriasis Lichenoides; Vasculitis, Leukocytoclastic, Cutaneous

2020
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
    Journal of neuroimmunology, 2020, 08-15, Volume: 345

    Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2

2020
Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
    Journal of medical virology, 2021, Volume: 93, Issue:1

    Topics: COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; RNA, Viral; SARS-CoV-2

2021
Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:6

    Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2021
Multiple sclerosis and related disorders: Short report peripheral vascular events in a real-world cohort of multiple sclerosis patients using Fingolimod.
    Multiple sclerosis and related disorders, 2020, Volume: 45

    Topics: Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies

2020
Long-term outcome in multiple sclerosis patients treated with fingolimod.
    Multiple sclerosis and related disorders, 2020, Volume: 45

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Longitudinal Studies; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome

2020
Fingolimod-induced immune thrombocytopenic purpura (ITP).
    Clinical neurology and neurosurgery, 2020, Volume: 197

    Topics: Adult; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Purpura, Thrombocytopenic, Idiopathic; Sphingosine 1 Phosphate Receptor Modulators; Treatment Outcome

2020
An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy.
    Journal of neuroimmunology, 2020, 10-15, Volume: 347

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; K562 Cells; Killer Cells, Natural; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Transcriptome; Young Adult

2020
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
    Annals of clinical and translational neurology, 2020, Volume: 7, Issue:9

    Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Rituximab

2020
Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
    Multiple sclerosis and related disorders, 2020, Volume: 46

    Topics: Fingolimod Hydrochloride; France; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2020
Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:3

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Meningoencephalitis; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    Journal of neurology, 2021, Volume: 268, Issue:3

    Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:9

    Topics: Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2021
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:5

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Portugal; Retrospective Studies; Treatment Outcome

2021
Discordant disability data in multiple sclerosis phase 3 studies among sphingosine-1- receptor modulator drugs.
    Multiple sclerosis and related disorders, 2020, Volume: 46

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pharmaceutical Preparations; Sphingosine

2020
Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.
    Journal of the neurological sciences, 2020, 11-15, Volume: 418

    Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting

2020
The expression analyses of RMRP, DDX5, and RORC in RRMS patients treated with different drugs versus naïve patients and healthy controls.
    Gene, 2021, Feb-15, Volume: 769

    Topics: Adult; Case-Control Studies; DEAD-box RNA Helicases; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nuclear Receptor Subfamily 1, Group F, Member 3; RNA, Long Noncoding; Young Adult

2021
Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
    Journal of medical economics, 2020, Volume: 23, Issue:12

    Topics: Canada; Child; Cost-Benefit Analysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferons; Markov Chains; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Quality-Adjusted Life Years

2020
Fingolimod in multiple sclerosis: profile of use in habitual practice.
    European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:6

    Topics: Adult; Electronic Health Records; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies

2020
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:10

    Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome

2021
Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
    Ear, nose, & throat journal, 2022, Volume: 101, Issue:10

    Topics: Anosmia; Dimethyl Fumarate; Fatigue; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2022
Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
    Multiple sclerosis and related disorders, 2021, Volume: 47

    Topics: Cognition; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Thalamus

2021
Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
    Neurology(R) neuroimmunology & neuroinflammation, 2021, Volume: 8, Issue:1

    Topics: Adjuvants, Immunologic; Antiviral Agents; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Interferon beta-1a; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines

2021
Usage trend of oral drugs for multiple sclerosis patients in Argentina.
    Multiple sclerosis and related disorders, 2021, Volume: 47

    Topics: Argentina; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pharmaceutical Preparations; Retrospective Studies

2021
Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study.
    Multiple sclerosis and related disorders, 2021, Volume: 48

    Topics: Brain; Diffusion Tensor Imaging; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pilot Projects; White Matter

2021
Multimodal MRI Response to Fingolimod in Multiple Sclerosis: A Nonrandomized, Single Arm, Observational Study.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2021, Volume: 31, Issue:2

    Topics: Adult; Anisotropy; Brain; Diffusion Tensor Imaging; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Treatment Outcome

2021
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
    Neurology, 2021, 02-02, Volume: 96, Issue:5

    Topics: Adult; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Proportional Hazards Models

2021
Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS.
    Multiple sclerosis and related disorders, 2021, Volume: 48

    Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Young Adult

2021
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
    Multiple sclerosis and related disorders, 2021, Volume: 48

    Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Isolated neurosarcoidosis mimicking multiple sclerosis.
    Neurosciences (Riyadh, Saudi Arabia), 2020, Volume: 25, Issue:5

    Topics: Adult; Central Nervous System Diseases; Cerebellum; Diagnostic Errors; Fingolimod Hydrochloride; Humans; Immunologic Factors; Infliximab; Magnetic Resonance Imaging; Male; Meninges; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Sarcoidosis; Spinal Cord

2020
Two-year follow-up during fingolimod treatment in a pediatric multiple sclerosis patient still active on first-line treatment.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Adolescent; Child; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Retrospective Studies

2021
Fingolimod in pediatric multiple sclerosis: three case reports.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Adolescent; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2021
Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:2

    Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Time Factors

2021
Relationships of total leukocyte, neutrophil and lymphocyte levels with the menstrual cycle in patients receiving fingolimod treatment.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Cell Proliferation; Female; Fingolimod Hydrochloride; Humans; Leukocytes; Lymphocyte Count; Lymphocytes; Lymphopenia; Menstrual Cycle; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neutrophils; Young Adult

2021
Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2021, Volume: 49

    Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma, B-Cell; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Oxidative stress activity of fingolimod in multiple sclerosis.
    Clinical neurology and neurosurgery, 2021, Volume: 202

    Topics: Adjuvants, Immunologic; Adult; Antioxidants; Case-Control Studies; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis, Relapsing-Remitting; Oxidants; Oxidative Stress; Sphingosine 1 Phosphate Receptor Modulators; Treatment Outcome

2021
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    BMC neurology, 2021, Feb-02, Volume: 21, Issue:1

    Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Symptom Flare Up

2021
Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996-2019).
    Multiple sclerosis and related disorders, 2021, Volume: 50

    Topics: Aged; Australia; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; National Health Programs; Tasmania

2021
Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod.
    Neurology(R) neuroimmunology & neuroinflammation, 2021, Volume: 8, Issue:3

    Topics: Fingolimod Hydrochloride; Histoplasmosis; Humans; Immunocompromised Host; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2021
Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study.
    Scientific reports, 2021, 02-18, Volume: 11, Issue:1

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Patient Safety; Surveys and Questionnaires

2021
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
    Journal of neurology, 2021, Volume: 268, Issue:9

    Topics: COVID-19; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2

2021
Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Adolescent; Bradycardia; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a "common" first line treatment.
    Revue neurologique, 2021, Volume: 177, Issue:8

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome

2021
Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
    BMJ case reports, 2021, Feb-26, Volume: 14, Issue:2

    Topics: Female; Fingolimod Hydrochloride; Hepatitis C; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:11

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome

2021
Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Adolescent; Child; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2021
Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
    Clinical neurology and neurosurgery, 2021, Volume: 203

    Topics: Adult; Africa, Northern; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle East; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome; Young Adult

2021
Efficacy of fingolimod after switching from interferon β-1a in an adolescent with multiple sclerosis: case report.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Adolescent; Adult; Child; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Long-term fingolimod treatment in two pediatric patients with multiple sclerosis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2021
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:1

    Topics: COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2

2022
Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting.
    European neurology, 2021, Volume: 84, Issue:3

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life

2021
Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment.
    Multiple sclerosis and related disorders, 2021, Volume: 51

    Topics: Aged; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies

2021
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies

2022
Multiple sclerosis hospitalizations among users of oral disease-modifying therapies.
    Multiple sclerosis and related disorders, 2021, Volume: 52

    Topics: Aged; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Hospitalization; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Toluidines; United States

2021
Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Adult; Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; United States

2021
Fingolimod in pediatric-onset multiple sclerosis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:Suppl 1

    Topics: Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study.
    Multiple sclerosis and related disorders, 2021, Volume: 52

    Topics: Adult; Antibodies, Monoclonal; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Rituximab

2021
Effect of fingolimod vs interferon treatment on OCT measurements and cognitive function in RRMS.
    Multiple sclerosis and related disorders, 2021, Volume: 53

    Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferons; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests

2021
Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity.
    Nature immunology, 2021, Volume: 22, Issue:7

    Topics: Adoptive Transfer; Animals; Autoimmunity; Brain; Calcium Signaling; Cell Lineage; Cerebrospinal Fluid; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gene Expression Profiling; Genes, T-Cell Receptor; HEK293 Cells; Humans; Immunosuppressive Agents; Intestines; Intravital Microscopy; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Multiple Sclerosis, Relapsing-Remitting; Phenotype; Prospective Studies; Receptors, CXCR6; Receptors, Purinergic P2X7; RNA-Seq; Single-Cell Analysis; Skin; T-Lymphocytes, Helper-Inducer; Transcriptome

2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
    Multiple sclerosis and related disorders, 2021, Volume: 53

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Treatment Outcome

2021
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Scientific reports, 2021, 06-15, Volume: 11, Issue:1

    Topics: Adult; Aged; Alemtuzumab; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasms; Nitriles; Outpatients; Proportional Hazards Models; Risk Factors; Smoking; Spain; Toluidines

2021
What happens after fingolimod discontinuation? A multicentre real-life experience.
    Journal of neurology, 2022, Volume: 269, Issue:2

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2022
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
    Multiple sclerosis and related disorders, 2021, Volume: 53

    Topics: Alemtuzumab; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2021
Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients.
    Molecular neurobiology, 2021, Volume: 58, Issue:10

    Topics: Adult; Cells, Cultured; Female; Fingolimod Hydrochloride; Follow-Up Studies; Gene Expression Profiling; Humans; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Male; Multiple Sclerosis, Relapsing-Remitting; Sphingosine 1 Phosphate Receptor Modulators; Transcriptome; Treatment Outcome; Wnt Signaling Pathway

2021
Five-year real-world data on fingolimod treatment's effects on cognitive function.
    Multiple sclerosis and related disorders, 2021, Volume: 54

    Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:3

    Topics: Adult; Cellular Senescence; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Killer Cells, Natural; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies

2021
Risk of depression in multiple sclerosis across disease-modifying therapies.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:4

    Topics: Depression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence

2022
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    Journal of neurology, 2022, Volume: 269, Issue:3

    Topics: Adult; Alemtuzumab; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2022
Therapeutic inertia in relapsing-remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2021, Volume: 55

    Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pregnancy

2021
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
    Current medical research and opinion, 2021, Volume: 37, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Azetidines; Benzyl Compounds; Clinical Trials, Phase III as Topic; Disease Progression; Feasibility Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propensity Score

2021
Severe lymphopenia switching from Fingolimod to Siponimod.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:11

    Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2021
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.
    European journal of neurology, 2021, Volume: 28, Issue:12

    Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2021
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
    Brain and behavior, 2017, Volume: 7, Issue:4

    Topics: Adult; Brain; Cohort Studies; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Failure

2017
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Adult; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Safety

2017
[Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Revista de neurologia, 2017, May-16, Volume: 64, Issue:10

    Topics: Adult; Contrast Media; Disability Evaluation; Disease-Free Survival; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroimaging; Oligoclonal Bands; Prospective Studies; Treatment Outcome; Young Adult

2017
Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:6

    Topics: Alemtuzumab; Cost-Benefit Analysis; Dimethyl Fumarate; Drug Costs; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Polyethylene Glycols; United States

2017
Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
    Neurologia, 2018, Volume: 33, Issue:5

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leishmaniasis, Cutaneous; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting

2018
Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Journal of clinical pharmacology, 2017, Volume: 57, Issue:11

    Topics: Brain; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Product Surveillance, Postmarketing

2017
Fatigue evaluation in fingolimod treated patients: An observational study.
    Multiple sclerosis and related disorders, 2017, Volume: 14

    Topics: Adult; Fatigue; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Treatment Outcome; Young Adult

2017
Fingolimod-associated macular oedema.
    BMJ case reports, 2017, Jun-15, Volume: 2017

    Topics: Anti-Inflammatory Agents; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prednisolone; Tomography, Optical Coherence

2017
Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
    Journal of medical economics, 2017, Volume: 20, Issue:9

    Topics: Adult; Alemtuzumab; Cost-Benefit Analysis; Female; Fingolimod Hydrochloride; Health Expenditures; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Prescription Fees; Quality-Adjusted Life Years; State Medicine; United Kingdom

2017
[Early onset of fingolimod-associated macular edema].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2018, Volume: 115, Issue:5

    Topics: Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Macular Edema; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2018
Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments.
    Journal of comparative effectiveness research, 2017, Volume: 6, Issue:5

    Topics: Administration, Oral; Adult; Anxiety; Cross-Sectional Studies; Depression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2017
Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:2

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2018
Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    BMC neurology, 2017, Aug-07, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Cohort Studies; Disabled Persons; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Recurrence; Young Adult

2017
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:11

    Topics: Adult; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence

2018
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:12

    Topics: Adult; Cladribine; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Treatment Outcome

2018
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:7

    Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Recurrence

2018
Ventricular tachycardia after initiation of fingolimod.
    BMJ case reports, 2017, Sep-27, Volume: 2017

    Topics: Diagnosis, Differential; Electrocardiography; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Tachycardia, Ventricular

2017
Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Journal of the neurological sciences, 2017, 10-15, Volume: 381

    Topics: Carcinoma, Merkel Cell; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms

2017
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.
    Brain and behavior, 2017, Volume: 7, Issue:10

    Topics: Adult; Cell Movement; Cohort Studies; Drug Monitoring; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infections; Italy; Liver Function Tests; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Risk Assessment; Secondary Prevention; Sex Factors

2017
Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2018, Volume: 48

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Mycosis Fungoides; Skin; Skin Neoplasms; Treatment Outcome

2018
Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Multiple sclerosis and related disorders, 2018, Volume: 19

    Topics: Adult; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Follow-Up Studies; Heart Block; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2018
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Journal of the neurological sciences, 2017, Dec-15, Volume: 383

    Topics: Adult; Atrophy; Brain; Disability Evaluation; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult

2017
Real-life clinical use of natalizumab and fingolimod in Austria.
    Acta neurologica Scandinavica, 2018, Volume: 137, Issue:2

    Topics: Adult; Austria; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Registries; Treatment Outcome; Young Adult

2018
Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.
    Journal of the neurological sciences, 2017, 12-15, Volume: 383

    Topics: Adult; Female; Fingolimod Hydrochloride; Gait; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Multiple Sclerosis, Relapsing-Remitting; Pilot Projects; Prospective Studies; Time Factors; Treatment Outcome

2017
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcom
    CNS drugs, 2018, Volume: 32, Issue:1

    Topics: Adult; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome; Young Adult

2018
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    JAMA neurology, 2018, 03-01, Volume: 75, Issue:3

    Topics: Adult; Cohort Studies; Community Health Planning; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Patient Selection; Rituximab; Sweden; Treatment Outcome

2018
Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments.
    CNS neuroscience & therapeutics, 2018, Volume: 24, Issue:5

    Topics: Adult; Axons; Brain; Diffusion Tensor Imaging; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath; Neural Pathways; Neuroprotective Agents; Treatment Outcome; White Matter

2018
The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:5

    Topics: Dimethyl Fumarate; Drug Utilization; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Off-Label Use; Rituximab

2018
Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.
    European journal of neurology, 2018, Volume: 25, Issue:5

    Topics: Adult; Aged; Cross-Sectional Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Switzerland; Treatment Outcome; Young Adult

2018
Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Multiple sclerosis and related disorders, 2018, Volume: 20

    Topics: Adult; Brain; Contrast Media; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunologic Factors; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Spinal Cord; Treatment Outcome

2018
A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
    Multiple sclerosis and related disorders, 2018, Volume: 21

    Topics: Dextrocardia; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Pregnancy, Unplanned

2018
Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.
    International ophthalmology, 2019, Volume: 39, Issue:4

    Topics: Adult; Analysis of Variance; Female; Fingolimod Hydrochloride; Fovea Centralis; Humans; Immunosuppressive Agents; Macula Lutea; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Tomography, Optical Coherence

2019
Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    PloS one, 2018, Volume: 13, Issue:3

    Topics: Adult; Animals; Antirheumatic Agents; Biomarkers; Disease Progression; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Drug Substitution; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Interferon-beta; Lymphocyte Count; Male; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recombinant Fusion Proteins; Retrospective Studies; Semaphorins; Severity of Illness Index; Specific Pathogen-Free Organisms; Treatment Outcome

2018
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
    Expert review of clinical pharmacology, 2018, Volume: 11, Issue:5

    Topics: Adult; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome; Young Adult

2018
Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis".
    Multiple sclerosis and related disorders, 2018, Volume: 22

    Topics: Electrocardiography, Ambulatory; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2018
Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
    Annals of neurology, 2018, Volume: 83, Issue:5

    Topics: Adult; Blood-Brain Barrier; Female; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Permeability; White Matter

2018
Comparisons of therapies in different scenarios help complete the puzzle.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:6

    Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2018
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:6

    Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Treatment Outcome

2018
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Journal of neurology, 2018, Volume: 265, Issue:7

    Topics: Adult; Alemtuzumab; Antineoplastic Agents, Immunological; Cohort Studies; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult

2018
Rebound disease in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:8

    Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2018
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:8

    Topics: Adult; Astrocytes; Autopsy; Brain; Fatal Outcome; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Recurrence

2018
HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod.
    Multiple sclerosis and related disorders, 2018, Volume: 23

    Topics: Carcinoma, Squamous Cell; Fingolimod Hydrochloride; Human papillomavirus 16; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Papillomavirus Infections; Tonsillar Neoplasms

2018
Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018, Volume: 39, Issue:8

    Topics: Adult; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Statistics, Nonparametric; Time Factors; Vitamin D

2018
Clinical activity after fingolimod cessation: disease reactivation or rebound?
    European journal of neurology, 2018, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Withholding Treatment; Young Adult

2018
Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
    Journal of medical economics, 2018, Volume: 21, Issue:10

    Topics: Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Health Services; Humans; Immunosuppressive Agents; Male; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Netherlands

2018
When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
    Journal of medical economics, 2018, Volume: 21, Issue:10

    Topics: Adult; Alemtuzumab; Cost-Benefit Analysis; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Health Resources; Health Services; Humans; Immunosuppressive Agents; Male; Markov Chains; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Technology Assessment, Biomedical

2018
Primary cutaneous CD30
    The British journal of dermatology, 2018, Volume: 179, Issue:6

    Topics: Biopsy; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Skin; Skin Neoplasms; T-Lymphocytes

2018
Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy.
    Scientific data, 2018, 07-24, Volume: 5

    Topics: B-Lymphocytes; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Microarray Analysis; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; T-Lymphocyte Subsets; Transcriptome

2018
[Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
    Revista de neurologia, 2018, Sep-01, Volume: 67, Issue:5

    Topics: Adult; Disease Progression; Drug Resistance; Drug Substitution; Female; Fingolimod Hydrochloride; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies

2018
Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.
    Journal of autoimmunity, 2019, Volume: 96

    Topics: Adult; Cell Plasticity; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunophenotyping; Lymphocyte Activation; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Young Adult

2019
Learning ability correlates with brain atrophy and disability progression in RRMS.
    Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:1

    Topics: Adult; Aptitude; Atrophy; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Learning; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic

2019
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Journal of neurology, 2018, Volume: 265, Issue:12

    Topics: Adult; Cohort Studies; Crotonates; Delayed-Action Preparations; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Germany; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Registries; Toluidines; Treatment Outcome

2018
Blinded continuous monitoring in clinical trials with recurrent event endpoints.
    Pharmaceutical statistics, 2019, Volume: 18, Issue:1

    Topics: Age Factors; Biostatistics; Computer Simulation; Data Interpretation, Statistical; Endpoint Determination; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Models, Statistical; Monte Carlo Method; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Recurrence; Research Design; Sample Size; Time Factors; Treatment Outcome

2019
Multiple Sclerosis Drug Fingolimod Induces Thrombotic Microangiopathy in Deoxycorticosterone Acetate/Salt Hypertension.
    Hypertension (Dallas, Tex. : 1979), 2018, Volume: 72, Issue:3

    Topics: Animals; Arterioles; Blood Pressure; Desoxycorticosterone Acetate; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Hypertension; Kidney; Male; Multiple Sclerosis, Relapsing-Remitting; Nephrectomy; Nitric Oxide Synthase Type III; Rats, Sprague-Dawley; Sodium Chloride; Thrombotic Microangiopathies

2018
Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
    Multiple sclerosis (Houndmills, Basingstoke, England), 2019, Volume: 25, Issue:11

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Papillomavirus Infections; Warts

2019
Warts and all: Fingolimod and unusual HPV-associated lesions.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2019, Volume: 25, Issue:11

    Topics: Ankle; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cryotherapy; Fingers; Fingolimod Hydrochloride; Foot Dermatoses; Hand Dermatoses; Humans; Imiquimod; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Papillomavirus Infections; Warts

2019
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
    Journal of neurology, 2019, Volume: 266, Issue:1

    Topics: Adult; Alemtuzumab; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunomodulation; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies; Treatment Outcome

2019
Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
    Multiple sclerosis and related disorders, 2019, Volume: 27

    Topics: Adult; Bradycardia; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Male; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Retrospective Studies

2019
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Journal of medical economics, 2019, Volume: 22, Issue:3

    Topics: Alemtuzumab; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Health Services; Health Status Indicators; Humans; Immunosuppressive Agents; Interferon-beta; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Quality-Adjusted Life Years

2019
Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
    Iranian journal of allergy, asthma, and immunology, 2018, Aug-12, Volume: 17, Issue:4

    Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Female; Fingolimod Hydrochloride; Flow Cytometry; Follow-Up Studies; Humans; Immunosuppressive Agents; Interferon Regulatory Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocyte Subsets; Young Adult

2018
Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Journal of medical economics, 2019, Volume: 22, Issue:4

    Topics: Adult; Cost of Illness; Cost-Benefit Analysis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Iran; Male; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Quality-Adjusted Life Years; Severity of Illness Index

2019
The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    Journal of neuroimmunology, 2019, 03-15, Volume: 328

    Topics: Adult; Case-Control Studies; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Seroepidemiologic Studies

2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:4

    Topics: Adult; Cohort Studies; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Proportional Hazards Models; Recurrence; Toluidines

2019
A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
    PloS one, 2019, Volume: 14, Issue:1

    Topics: Canada; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Insurance Claim Review; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Patient Compliance; Retrospective Studies; Toluidines

2019
Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology, 2019, 01-15, Volume: 92, Issue:3

    Topics: Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2019
Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology, 2019, 01-15, Volume: 92, Issue:3

    Topics: Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    JAMA, 2019, 01-15, Volume: 321, Issue:2

    Topics: Adult; Alemtuzumab; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Time-to-Treatment

2019
Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
    Acta neurologica Scandinavica, 2019, Volume: 139, Issue:5

    Topics: Adult; Biomarkers; CD56 Antigen; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2019
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    Journal of neurology, 2019, Volume: 266, Issue:3

    Topics: Adult; Alemtuzumab; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Rituximab

2019
Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis?
    The American journal of case reports, 2019, Jan-24, Volume: 20

    Topics: Adult; Brain; DNA, Viral; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting

2019
Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, Volume: 22, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cost-Benefit Analysis; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome; United States; Young Adult

2019
Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis.
    Journal of the neurological sciences, 2019, Mar-15, Volume: 398

    Topics: Adult; Cohort Studies; Databases, Factual; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Insurance Claim Review; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Time Factors; United States

2019
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
    European journal of neurology, 2019, Volume: 26, Issue:8

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Retrospective Studies; Rituximab; Sweden; Treatment Outcome

2019
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    JAMA neurology, 2019, 05-01, Volume: 76, Issue:5

    Topics: Activities of Daily Living; Adolescent; Adult; Alemtuzumab; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Early Medical Intervention; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Retrospective Studies; Toluidines; Treatment Outcome; Young Adult

2019
Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients.
    Scientific reports, 2019, 02-19, Volume: 9, Issue:1

    Topics: Adenosine Triphosphatases; Adult; Antigens, CD; Apyrase; Cells, Cultured; Female; Fingolimod Hydrochloride; Flow Cytometry; Glatiramer Acetate; Humans; Leukocytes, Mononuclear; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peripheral Blood Stem Cells; T-Lymphocytes, Regulatory

2019
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Clinical therapeutics, 2019, Volume: 41, Issue:2

    Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines

2019
Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.
    Neurology(R) neuroimmunology & neuroinflammation, 2019, Volume: 6, Issue:3

    Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Prospective Studies; Time Factors

2019
The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:4

    Topics: Administration, Oral; Cost-Benefit Analysis; Drug Costs; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Injections; Interferon beta-1a; Managed Care Programs; Markov Chains; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Reimbursement Mechanisms; United States

2019
Real-life use of oral disease-modifying treatments in Austria.
    Acta neurologica Scandinavica, 2019, Volume: 140, Issue:1

    Topics: Administration, Oral; Adult; Austria; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Recurrence; Registries; Toluidines

2019
Detection of a new melanoma in a patient treated with fingolimod.
    BMJ case reports, 2019, Apr-29, Volume: 12, Issue:4

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nevus, Pigmented; Skin Neoplasms; Treatment Outcome; Withholding Treatment

2019
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
    Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:12

    Topics: Adult; Alemtuzumab; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Integrin alpha4; Leukocyte Count; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuromuscular Agents; Recurrence; Retrospective Studies

2019
Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2019, Volume: 46, Issue:4

    Topics: Adult; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Treatment Outcome

2019
The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
    Multiple sclerosis and related disorders, 2019, Volume: 33

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Italy; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies

2019
Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Jul-18, Volume: 76, Issue:15

    Topics: Administration, Oral; Community Networks; Community Pharmacy Services; Delivery of Health Care, Integrated; Female; Fingolimod Hydrochloride; Humans; Medication Adherence; Medication Therapy Management; Motivational Interviewing; Multiple Sclerosis, Relapsing-Remitting; Patient Education as Topic; Patient Safety; Patient Transfer; Pharmacists; Pharmacovigilance; Program Development; Switzerland

2019
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Journal of neurology, 2019, Volume: 266, Issue:10

    Topics: Adult; Alemtuzumab; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Retrospective Studies; Severity of Illness Index

2019
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Expert review of pharmacoeconomics & outcomes research, 2020, Volume: 20, Issue:3

    Topics: Adult; Cladribine; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; Spain

2020
Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
    Multiple sclerosis and related disorders, 2019, Volume: 34

    Topics: Adult; B-Lymphocytes; Brain-Derived Neurotrophic Factor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Inflammation; Interleukin-2; Male; Multiple Sclerosis, Relapsing-Remitting; Receptors, CXCR4; T-Lymphocytes; Transforming Growth Factor beta; Treatment Outcome

2019
Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient.
    Multiple sclerosis and related disorders, 2019, Volume: 34

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Adherence and Compliance

2019
Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis.
    Journal of the neurological sciences, 2019, Aug-15, Volume: 403

    Topics: Adolescent; Adult; Aged; Atrophy; Brain; Disease Progression; Early Medical Intervention; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Young Adult

2019
Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
    Journal of the neurological sciences, 2019, Aug-15, Volume: 403

    Topics: Adult; Constriction, Pathologic; Female; Fingolimod Hydrochloride; Herpesvirus 3, Human; Humans; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Risk Factors; Vascular Diseases

2019
Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    Journal of neurology, 2019, Volume: 266, Issue:11

    Topics: Adult; Austria; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Treatment Outcome

2019
Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
    Clinical neurology and neurosurgery, 2019, Volume: 184

    Topics: Adult; Disabled Persons; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Poland; Recurrence

2019
Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data.
    Biometrics, 2013, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Clinical Trials, Phase III as Topic; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult

2013
Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade.
    The Journal of allergy and clinical immunology, 2013, Volume: 131, Issue:5

    Topics: Case-Control Studies; Chemotaxis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets

2013
Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:9

    Topics: Brain; CD4-Positive T-Lymphocytes; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, CCR7; Sphingosine; Young Adult

2013
[The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:2 Pt 2

    Topics: Administration, Oral; Adult; Blood Pressure; Electrocardiography; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Monitoring, Physiologic; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine; Treatment Outcome

2013
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:13

    Topics: Antibodies, Monoclonal, Humanized; Australia; Drug Prescriptions; Fingolimod Hydrochloride; Geography; Humans; Immunologic Factors; Interferon-beta; Linear Models; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Pharmacoepidemiology; Prevalence; Propylene Glycols; Pyridostigmine Bromide; Riluzole; Sphingosine

2013
Management of fingolimod-associated macular edema.
    JAMA ophthalmology, 2013, Volume: 131, Issue:5

    Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dexamethasone; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Glucocorticoids; Humans; Immunosuppressive Agents; Intraocular Pressure; Ketorolac Tromethamine; Macular Edema; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity

2013
Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
    JAMA ophthalmology, 2013, Volume: 131, Issue:6

    Topics: Administration, Oral; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Glucocorticoids; Humans; Immunosuppressive Agents; Injections, Intraocular; Macular Edema; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone

2013
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
    Journal of neurology, 2013, Volume: 260, Issue:6

    Topics: Age of Onset; Brain; Child; Cyclophosphamide; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Plasma Exchange; Propylene Glycols; Sphingosine; Young Adult

2013
Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
    Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2013, Volume: 8, Issue:5

    Topics: CD8-Positive T-Lymphocytes; Cytokines; Fingolimod Hydrochloride; Humans; Immunophenotyping; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory

2013
Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    The American journal of managed care, 2013, Volume: 19, Issue:4

    Topics: Adult; Antibodies, Monoclonal, Humanized; Comparative Effectiveness Research; Cost-Benefit Analysis; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; JC Virus; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quality-Adjusted Life Years; Recurrence; Sphingosine

2013
Rebound of disease activity during pregnancy after withdrawal of fingolimod.
    European journal of neurology, 2013, Volume: 20, Issue:8

    Topics: Adult; Anti-Inflammatory Agents; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine

2013
Fingolimod therapy and macular hemorrhage.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2013, Volume: 33, Issue:4

    Topics: Blindness; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Hemorrhage; Humans; Immunosuppressive Agents; Macula Lutea; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence

2013
Fingolimod in a patient with Wolff-Parkinson-White syndrome.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:5

    Topics: Adult; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Wolff-Parkinson-White Syndrome

2014
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.
    Journal of neurology, 2013, Volume: 260, Issue:12

    Topics: Adult; Antibodies, Monoclonal, Humanized; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outpatients; Propylene Glycols; Recurrence; Sphingosine

2013
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
    Acta neurologica Scandinavica, 2014, Volume: 129, Issue:3

    Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Time Factors

2014
Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Neurologia (Barcelona, Spain), 2014, Volume: 29, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Cost Control; Drug Costs; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Spain; Sphingosine

2014
Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
    Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2013, Volume: 8, Issue:5

    Topics: CD8-Positive T-Lymphocytes; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory

2013
Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:3

    Topics: Administration, Oral; Atrioventricular Block; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult

2014
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:4

    Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine

2014
Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine

2014
Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Cohort Studies; Databases, Factual; Demography; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Insurance Claim Review; Interferons; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Propylene Glycols; Recurrence; Sphingosine; Time Factors; United States

2014
Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:12

    Topics: Adult; Angioedema; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Knee; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Skin; Sphingosine; Sphingosine-1-Phosphate Receptors

2014
Fingolimod after natalizumab and the risk of short-term relapse.
    Neurology, 2014, Apr-08, Volume: 82, Issue:14

    Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Risk Factors; Secondary Prevention; Sphingosine; Treatment Outcome

2014
Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.
    Neurology, 2014, Apr-08, Volume: 82, Issue:14

    Topics: Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine

2014
Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
    Clinical neurology and neurosurgery, 2014, Volume: 119

    Topics: Adult; Brain; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kuwait; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Retrospective Studies; Sphingosine; Treatment Outcome; Young Adult

2014
Effects of fingolimod in relapsing-remitting multiple sclerosis.
    The Lancet. Neurology, 2014, Volume: 13, Issue:6

    Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome

2014
Ventricular arrhythmia in a male MS patient on fingolimod.
    Acta neurologica Belgica, 2015, Volume: 115, Issue:1

    Topics: Arrhythmias, Cardiac; Electrocardiography; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2015
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2014, Volume: 35, Issue:9

    Topics: Adult; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Lymphopenia; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2014
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Current medical research and opinion, 2014, Volume: 30, Issue:9

    Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome

2014
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:13

    Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Retrospective Studies; Risk Factors; Sphingosine

2014
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:10

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Biomarkers; Contrast Media; Databases, Factual; Disease-Free Survival; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Predictive Value of Tests; Propylene Glycols; Retrospective Studies; Serologic Tests; Sphingosine; Time Factors; Treatment Outcome

2014
Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:13

    Topics: Adult; Asthma; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2014
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
    BMC neurology, 2014, Jun-07, Volume: 14

    Topics: Coronary Artery Disease; Female; Fingolimod Hydrochloride; Heart Failure; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2014
The autonomic balance predicts cardiac responses after the first dose of fingolimod.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:2

    Topics: Adult; Autonomic Nervous System; Bradycardia; Female; Fingolimod Hydrochloride; Heart Function Tests; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Parasympathetic Nervous System

2015
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
    European journal of neurology, 2015, Volume: 22, Issue:3

    Topics: Adult; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies

2015
Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    CNS drugs, 2014, Volume: 28, Issue:9

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kuwait; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Registries; Retrospective Studies; Severity of Illness Index; Sphingosine; Treatment Outcome

2014
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2015, Volume: 126, Issue:1

    Topics: Administration, Oral; Adult; Animals; Evoked Potentials, Motor; Female; Fingolimod Hydrochloride; Glutamic Acid; Humans; Immunosuppressive Agents; Male; Middle Aged; Motor Cortex; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Prospective Studies; Sphingosine; Transcranial Magnetic Stimulation

2015
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Administration, Oral; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting

2014
Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.
    BMC neurology, 2014, Aug-20, Volume: 14

    Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2014
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    European neurology, 2014, Volume: 72, Issue:3-4

    Topics: Adult; Antibodies, Monoclonal, Humanized; Brain; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Kaplan-Meier Estimate; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Observation; Propylene Glycols; Retrospective Studies; Severity of Illness Index; Sphingosine; Treatment Outcome

2014
Recurrence of disease activity after repeated Natalizumab withdrawals.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015, Volume: 36, Issue:3

    Topics: Adult; Disease-Free Survival; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Young Adult

2015
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:6

    Topics: Adult; Clinical Trials, Phase III as Topic; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Time Factors; Treatment Outcome

2015
Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:5

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2015
Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events with Unequal Follow-Up Time.
    Journal of biopharmaceutical statistics, 2015, Volume: 25, Issue:5

    Topics: Computer Simulation; Data Interpretation, Statistical; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Numerical Analysis, Computer-Assisted; Randomized Controlled Trials as Topic; Recurrence; Sample Size; Time Factors; Treatment Outcome

2015
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
    CNS drugs, 2015, Volume: 29, Issue:1

    Topics: Adolescent; Adult; Cohort Studies; Cost-Benefit Analysis; Dimethyl Fumarate; Disability Evaluation; Female; Fingolimod Hydrochloride; Fumarates; Humans; Immunologic Factors; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Male; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine; Young Adult

2015
Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Aged; B-Lymphocyte Subsets; B7-1 Antigen; B7-2 Antigen; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Young Adult

2014
Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:6

    Topics: Adult; B-Lymphocytes; Cell Proliferation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets

2015
Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    European neurology, 2015, Volume: 73, Issue:1-2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment Outcome

2015
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Advances in therapy, 2014, Volume: 31, Issue:11

    Topics: Administration, Oral; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Patient Acuity; Randomized Controlled Trials as Topic; Recurrence; Toluidines

2014
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    Journal of medical economics, 2015, Volume: 18, Issue:4

    Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Secondary Prevention; Sweden

2015
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Journal of the neurological sciences, 2015, Jan-15, Volume: 348, Issue:1-2

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Hypothyroidism; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Young Adult

2015
Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:12

    Topics: Adult; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, CCR7; T-Lymphocytes, Regulatory; Thymus Gland; Young Adult

2015
A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure.
    BMC pharmacology & toxicology, 2015, Apr-01, Volume: 16

    Topics: Electrocardiography; Fingolimod Hydrochloride; Guideline Adherence; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Retrospective Studies; Switzerland

2015
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
    Journal of neuroimmunology, 2015, May-15, Volume: 282

    Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult

2015
Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:7

    Topics: Brain; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting

2015
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Neurology, 2015, Jun-09, Volume: 84, Issue:23

    Topics: Adult; Encephalitis, Herpes Simplex; Fingolimod Hydrochloride; Herpesvirus 1, Human; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Virus Activation

2015
Postoperative cystoid macular oedema in a patient on fingolimod.
    BMJ case reports, 2015, May-12, Volume: 2015

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Diclofenac; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Ophthalmic Solutions; Prednisolone

2015
Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.
    Multiple sclerosis and related disorders, 2015, Volume: 4, Issue:3

    Topics: Adult; Citalopram; Clinical Trials as Topic; Drug Therapy, Combination; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Rate; Humans; Male; Multiple Sclerosis, Relapsing-Remitting; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2015
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
    Neurology, 2015, Jul-07, Volume: 85, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Drug Substitution; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine

2015
Fingolimod effects on left ventricular function in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:2

    Topics: Adult; Case-Control Studies; Echocardiography; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Stroke Volume; Systole; Ventricular Function, Left

2016
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Journal of medical economics, 2015, Volume: 18, Issue:11

    Topics: Cost-Benefit Analysis; Dimethyl Fumarate; Disability Evaluation; Disease Progression; England; Fingolimod Hydrochloride; Health Status; Humans; Immunosuppressive Agents; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; State Medicine

2015
The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.
    BMC neurology, 2015, Jun-18, Volume: 15

    Topics: Drug Industry; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Patient Safety; Product Surveillance, Postmarketing; Propylene Glycols; Prospective Studies; Quality of Life; Research Design

2015
Effects of Three Months Fingolimod Therapy on Heart Rate.
    Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2015, Volume: 10, Issue:4

    Topics: Adult; Electrocardiography; Female; Fingolimod Hydrochloride; Follow-Up Studies; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Monitoring, Ambulatory; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2015
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
    BMC neurology, 2015, Jun-23, Volume: 15

    Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Risk

2015
[Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Ideggyogyaszati szemle, 2014, Mar-30, Volume: 67, Issue:3-4

    Topics: Antibodies, Monoclonal, Humanized; Disease-Free Survival; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Treatment Outcome

2014
Safety and efficacy of reduced fingolimod dosage treatment.
    Journal of neuroimmunology, 2015, Aug-15, Volume: 285

    Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Liver Function Tests; Lymphocytes; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult

2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:4

    Topics: Administration, Oral; Adult; Aged; Demyelinating Diseases; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Time Factors; Treatment Outcome

2016
Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:1

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphomatoid Papulosis; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms

2016
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:11

    Topics: Adult; Cerebrovascular Disorders; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Parturition; Pregnancy; Syndrome; Vasoconstriction

2015
Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations.
    Multiple sclerosis and related disorders, 2015, Volume: 4, Issue:5

    Topics: Acetazolamide; Administration, Oral; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis, Relapsing-Remitting; Optic Neuritis; Visual Acuity; Young Adult

2015
Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:5

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sphingosine; Ventricular Function, Left

2016
Comment on "Fingolimod effects on left ventricular function in multiple sclerosis" Mult Scler 2015.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:5

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Ventricular Function, Left

2016
Prediction of disability progression in fingolimod-treated patients.
    Journal of the neurological sciences, 2015, Nov-15, Volume: 358, Issue:1-2

    Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Prognosis

2015
Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:8

    Topics: Adult; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Parasympathetic Nervous System; Prospective Studies; Sex Factors; Sympathetic Nervous System; Time Factors; Treatment Outcome

2016
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Brain : a journal of neurology, 2015, Volume: 138, Issue:Pt 11

    Topics: Adult; Cohort Studies; Drug Substitution; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Poisson Distribution; Prospective Studies; Registries; Regression Analysis; Treatment Outcome

2015
[Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2015, Sep-01, Volume: 39, Issue:5

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab

2015
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:4

    Topics: Adult; Ankle; Female; Fingolimod Hydrochloride; Humans; Melanoma; Melanoma, Cutaneous Malignant; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms

2016
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:10

    Topics: Adolescent; Adult; Atrophy; Brain; Clinical Trials, Phase III as Topic; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Treatment Outcome; Young Adult

2016
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    Journal of neurology, 2016, Volume: 263, Issue:2

    Topics: Adult; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2016
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
    Statistics in medicine, 2016, 05-30, Volume: 35, Issue:12

    Topics: Clinical Trials, Phase III as Topic; Drug Labeling; Endpoint Determination; Fingolimod Hydrochloride; Humans; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Random Allocation; Randomized Controlled Trials as Topic; Research Design; Sample Size; Single-Blind Method

2016
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Journal of medical economics, 2016, Volume: 19, Issue:4

    Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years

2016
Efficacy and Safety of Fingolimod in an Unselected Patient Population.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adult; Aged; Case-Control Studies; Cytokines; Dyspnea; Edema; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies

2016
The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2016, Volume: 5

    Topics: Adult; Blood Pressure; Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Monitoring, Physiologic; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome; United Kingdom

2016
Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:7

    Topics: Adolescent; Biopsy; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Molluscum Contagiosum; Molluscum contagiosum virus; Multiple Sclerosis, Relapsing-Remitting; Opportunistic Infections; Risk Factors

2016
Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2016, Volume: 43, Issue:2

    Topics: Adolescent; Adult; Aged; Canada; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Registries; Young Adult

2016
Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2016, Volume: 30

    Topics: Brain Neoplasms; Female; Fingolimod Hydrochloride; Glioblastoma; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2016
Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    CNS neuroscience & therapeutics, 2016, Volume: 22, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Analysis of Variance; Cytokines; Disability Evaluation; Female; Fingolimod Hydrochloride; Flow Cytometry; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphocyte Subsets; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Phosphoproteins; Time Factors; Young Adult

2016
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    JAMA neurology, 2016, 07-01, Volume: 73, Issue:7

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; PubMed; Recurrence

2016
Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod.
    CNS neuroscience & therapeutics, 2016, Volume: 22, Issue:7

    Topics: Adult; Central Nervous System; Female; Fingolimod Hydrochloride; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting

2016
Fingolimod-associated PML in a patient with prior immunosuppression.
    Neurology, 2016, 05-10, Volume: 86, Issue:19

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2016
Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2016, Volume: 31

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Sarcoma, Kaposi

2016
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:10

    Topics: Adolescent; Adult; Databases, Factual; Deprescriptions; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferons; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Treatment Failure; Treatment Outcome; Young Adult

2016
Severe tumefactive rebound of multiple sclerosis following fingolimod cessation.
    BMJ case reports, 2016, Jun-03, Volume: 2016

    Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Naltrexone; Narcotic Antagonists; Recurrence; Withholding Treatment

2016
Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
    Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2016, Volume: 11, Issue:4

    Topics: Adult; Cardiovascular Diseases; Cohort Studies; Female; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Lipids; Male; Multiple Sclerosis, Relapsing-Remitting; Risk Factors; Treatment Outcome

2016
Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
    Medicine, 2016, Volume: 95, Issue:29

    Topics: Aged; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis, Relapsing-Remitting

2016
Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
    Multiple sclerosis and related disorders, 2016, Volume: 8

    Topics: Adult; Erythroblasts; Erythrocyte Count; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Interferons; Logistic Models; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prevalence; Retrospective Studies

2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.
    Annals of neurology, 2016, Volume: 80, Issue:5

    Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Rituximab

2016
Sometimes less is more in multiple sclerosis drug switching.
    Arquivos de neuro-psiquiatria, 2016, Volume: 74, Issue:8

    Topics: Drug Substitution; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Time Factors

2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Neurology, 2016, 09-06, Volume: 87, Issue:10

    Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols

2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Neurology, 2016, 09-06, Volume: 87, Issue:10

    Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols

2016
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
    BMC research notes, 2016, Sep-07, Volume: 9, Issue:1

    Topics: Adult; Aged; Cross-Sectional Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Health Surveys; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Satisfaction; Surveys and Questionnaires

2016
Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.
    Physiological reports, 2016, Volume: 4, Issue:17

    Topics: Adult; Autonomic Nervous System; Circadian Rhythm; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Sphingosine

2016
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
    Multiple sclerosis and related disorders, 2016, Volume: 9

    Topics: Adult; Dyspnea; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lung; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2016
Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Multiple sclerosis and related disorders, 2016, Volume: 9

    Topics: Aged; Fatal Outcome; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Meningitis, Cryptococcal; Mesencephalon; Multiple Sclerosis, Relapsing-Remitting

2016
Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2016, Volume: 9

    Topics: Adult; Brain; Cervical Cord; Female; Fingolimod Hydrochloride; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2016
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    JAMA neurology, 2016, 11-01, Volume: 73, Issue:11

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2016
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    JAMA neurology, 2016, 11-01, Volume: 73, Issue:11

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2016
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply.
    JAMA neurology, 2016, 11-01, Volume: 73, Issue:11

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting

2016
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:3

    Topics: Adult; Female; Fingolimod Hydrochloride; Hepatitis B; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Reverse Transcriptase Inhibitors

2017
Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies.
    Clinical immunology (Orlando, Fla.), 2016, Volume: 173

    Topics: Adult; Female; Fingolimod Hydrochloride; Gene Expression Profiling; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Leukocytes, Mononuclear; Male; Multiple Sclerosis, Relapsing-Remitting; Transcriptome; Young Adult

2016
Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
    Journal of neuroimmunology, 2016, 10-15, Volume: 299

    Topics: Adult; Biomarkers; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; MicroRNAs; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2016
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
    Scientific reports, 2016, 10-18, Volume: 6

    Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-gamma; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Phenotype; Sphingosine; T-Lymphocytes

2016
Early and recurrent macular oedema in a patient treated with fingolimod.
    Neurologia, 2019, Volume: 34, Issue:3

    Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Tomography, Optical Coherence

2019
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Clinical drug investigation, 2017, Volume: 37, Issue:2

    Topics: Adult; Czech Republic; Disability Evaluation; Disease Progression; Endpoint Determination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome; Work

2017
6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis.
    Journal of the American College of Cardiology, 2016, 11-01, Volume: 68, Issue:18

    Topics: Adult; Autonomic Nervous System; Baroreflex; Female; Fingolimod Hydrochloride; Heart; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting

2016
JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
    Journal of neurovirology, 2017, Volume: 23, Issue:2

    Topics: Adult; Antibodies, Viral; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroglia; Serine-Arginine Splicing Factors; Signal Transduction; Virus Activation

2017
Reversible cerebral vasoconstriction syndrome in association with fingolimod use.
    The International journal of neuroscience, 2017, Volume: 127, Issue:9

    Topics: Adult; Cerebral Angiography; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Vasoconstriction; Vasospasm, Intracranial

2017
Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Medical science monitor : international medical journal of experimental and clinical research, 2016, Nov-10, Volume: 22

    Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2016
Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology, 2016, 12-13, Volume: 87, Issue:24

    Topics: Carcinoma, Merkel Cell; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms

2016
Anxiety and Coping Strategy Changes in Multiple Sclerosis Patients Initiating Fingolimod: The GRACE Prospective Study.
    European neurology, 2017, Volume: 77, Issue:1-2

    Topics: Adaptation, Psychological; Adult; Anxiety; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies

2017
Early safety and efficacy of fingolimod treatment in Denmark.
    Acta neurologica Scandinavica, 2017, Volume: 135, Issue:1

    Topics: Adult; Aged; Cardiotoxicity; Denmark; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Respiration

2017
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Multiple sclerosis and related disorders, 2016, Volume: 10

    Topics: Adult; Brain; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Acceptance of Health Care; Retrospective Studies; Treatment Outcome

2016
Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
    Multiple sclerosis and related disorders, 2016, Volume: 10

    Topics: Adult; Disability Evaluation; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Prognosis

2016
A longitudinal real-life comparison study of natalizumab and fingolimod.
    Acta neurologica Scandinavica, 2017, Volume: 136, Issue:3

    Topics: Adolescent; Adult; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies

2017
A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Journal of medical economics, 2017, Volume: 20, Issue:5

    Topics: Computer Simulation; Cost-Benefit Analysis; Disability Evaluation; Fees, Pharmaceutical; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Quality-Adjusted Life Years; State Medicine; United Kingdom

2017
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    Journal of neuroimmunology, 2017, 02-15, Volume: 303

    Topics: Adult; Biomarkers; Cohort Studies; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphocyte Subsets; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome

2017
Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Neurology, 2017, Feb-14, Volume: 88, Issue:7

    Topics: Adult; Clinical Decision-Making; Decision Support Techniques; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Randomized Controlled Trials as Topic; Risk; Time Factors; Treatment Outcome

2017
Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
    BMC neurology, 2017, Jan-18, Volume: 17, Issue:1

    Topics: Adult; Aged; Atrioventricular Block; Bradycardia; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult

2017
Sequence of cardiovascular autonomic alterations after fingolimod initiation.
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2017, Volume: 22, Issue:5

    Topics: Adult; Autonomic Nervous System; Blood Pressure; Electrocardiography; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting

2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    The Lancet. Neurology, 2017, Volume: 16, Issue:4

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Cohort Studies; Databases, Bibliographic; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome; Young Adult

2017
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Multiple sclerosis (Houndmills, Basingstoke, England), 2017, Volume: 23, Issue:4

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome; White Matter

2017
Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:2

    Topics: Adult; Age Factors; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Recurrence; Retrospective Studies

2018
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
    Neurology, 2009, Mar-17, Volume: 72, Issue:11

    Topics: Adult; Brain; Cerebral Hemorrhage; Contrast Media; Encephalitis; Epilepsy, Complex Partial; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Necrosis; Propylene Glycols; Sphingosine

2009
Oral therapy for multiple sclerosis--sea change or incremental step?
    The New England journal of medicine, 2010, Feb-04, Volume: 362, Issue:5

    Topics: Administration, Oral; Arrhythmias, Cardiac; Cladribine; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2010
[Progress of therapy in patients with multiple sclerosis].
    MMW Fortschritte der Medizin, 2010, Mar-04, Volume: 152, Issue:9

    Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Brain; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Rituximab; Sphingosine

2010
Oral cladribine and fingolimod for relapsing multiple sclerosis.
    The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18

    Topics: Cladribine; Ethics, Research; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Informed Consent; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Research Design; Sphingosine

2010
Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis.
    Neurology, 2010, Jun-15, Volume: 74, Issue:24

    Topics: Adult; Arm; Blood Flow Velocity; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Vascular Diseases

2010
[Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].
    Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46 Suppl D

    Topics: Activities of Daily Living; Administration, Oral; Disability Evaluation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Recovery of Function; Sphingosine; Treatment Outcome

2010
CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2

    Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Fingolimod Hydrochloride; Humans; In Vitro Techniques; Mass Spectrometry; Microsomes, Liver; Molecular Structure; Multiple Sclerosis, Relapsing-Remitting; Oxidation-Reduction; Propylene Glycols; Sphingosine; Transfection

2011
FDA approves the first oral drug for reducing multiple sclerosis relapses.
    Harvard women's health watch, 2010, Volume: 18, Issue:4

    Topics: Administration, Oral; Central Nervous System; Drug Approval; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine; United States; United States Food and Drug Administration

2010
Primary varicella zoster infection associated with fingolimod treatment.
    Neurology, 2011, Mar-15, Volume: 76, Issue:11

    Topics: Acyclovir; Adult; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome

2011
Fingolimod modulates microglial activation to augment markers of remyelination.
    Journal of neuroinflammation, 2011, Jul-05, Volume: 8

    Topics: Animals; Biomarkers; Cell Culture Techniques; Cells, Cultured; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Microglia; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Myelin Sheath; Nerve Degeneration; Pregnancy; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Spheroids, Cellular; Sphingosine

2011
Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
    Nature reviews. Neurology, 2011, Jul-12, Volume: 7, Issue:8

    Topics: Cladribine; Clinical Trials as Topic; Device Approval; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2011
NICE rules out NHS prescription of fingolimod for multiple sclerosis.
    BMJ (Clinical research ed.), 2011, Aug-10, Volume: 343

    Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; National Health Programs; Prescription Drugs; Propylene Glycols; Sphingosine; Treatment Outcome

2011
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Journal of the neurological sciences, 2011, Volume: 311 Suppl 1

    Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Pharmacovigilance; Propylene Glycols; Risk Assessment; Sphingosine

2011
The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonists.
    Xenobiotica; the fate of foreign compounds in biological systems, 2012, Volume: 42, Issue:7

    Topics: Animals; Arrestin; Fingolimod Hydrochloride; GTP-Binding Proteins; Lymphocytes; Lysophospholipids; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Rats; Rats, Inbred Strains; Signal Transduction; Sphingosine

2012
Does fingolimod in multiple sclerosis patients cause macular edema?
    Journal of neurology, 2012, Volume: 259, Issue:2

    Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence

2012
Sudden unexpected death on fingolimod.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:10

    Topics: Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Fingolimod Hydrochloride; Humans; Hypertension; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2012
Fingolimod for multiple sclerosis.
    Drug and therapeutics bulletin, 2012, Volume: 50, Issue:2

    Topics: Administration, Oral; Drug Administration Schedule; Drug Approval; Drug Costs; Drug Information Services; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2012
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
    Archives of neurology, 2012, Volume: 69, Issue:2

    Topics: Brain; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome

2012
Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Neurology, 2012, Mar-20, Volume: 78, Issue:12

    Topics: Adult; Antibodies, Monoclonal, Humanized; Ataxia; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Plasma Exchange; Propylene Glycols; Recurrence; Sphingosine; Spine

2012
MS clinical trials: what can subgroup analyses teach us?
    The Lancet. Neurology, 2012, Volume: 11, Issue:5

    Topics: Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2012
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Journal of medical economics, 2012, Volume: 15, Issue:6

    Topics: Adult; Cost-Benefit Analysis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Markov Chains; Models, Econometric; Monte Carlo Method; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Quality-Adjusted Life Years; Sphingosine; United States

2012
[Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].
    Ideggyogyaszati szemle, 2012, May-30, Volume: 65, Issue:5-6

    Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Congresses as Topic; Contrast Media; European Union; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Posters as Topic; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Failure; Treatment Outcome

2012
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Journal of medical economics, 2012, Volume: 15, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Cost Savings; Costs and Cost Analysis; Fingolimod Hydrochloride; Health Services; Humans; Immunosuppressive Agents; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Netherlands; Propylene Glycols; Sphingosine

2012
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:11

    Topics: Adult; Disability Evaluation; Disease Progression; Drug Administration Schedule; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome

2012
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:11

    Topics: Adult; Antibodies, Monoclonal, Humanized; Asthenia; Disease Progression; Drug Administration Schedule; Drug Substitution; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Severity of Illness Index; Sphingosine; Time Factors; Treatment Outcome

2012
Early tolerability and safety of fingolimod in clinical practice.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Adult; Bradycardia; Chest Pain; Drug Substitution; Female; Fingolimod Hydrochloride; Headache; Humans; Hypertension; Lymphopenia; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nausea; Patient Acceptance of Health Care; Product Surveillance, Postmarketing; Propylene Glycols; Retrospective Studies; Sphingosine

2012
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:11

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Disability Evaluation; Drug Administration Schedule; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; JC Virus; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome

2012
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine

2013
Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Journal of medical economics, 2013, Volume: 16, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Cost of Illness; Costs and Cost Analysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Sweden

2013
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
    Journal of neurology, 2013, Volume: 260, Issue:5

    Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Time Factors; Young Adult

2013
Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:9

    Topics: Adult; Aged; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Neutropenia; Propylene Glycols; Sphingosine

2013
Switching from natalizumab to fingolimod: an observational study.
    Acta neurologica Scandinavica, 2013, Volume: 128, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; JC Virus; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Observation; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult

2013
Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Animals; Autoantigens; Cell Movement; Central Nervous System; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymph Nodes; Lysophospholipids; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes

2006